Document:

Amended and Restated Exclusive License Agreement

 EXHIBIT 10.8 
 AMENDED AND RESTATED 
 EXCLUSIVE LICENSE AGREEMENT 
 This amended and restated agreement (this “Agreement”) is made effective as of the 14th day of April 2008 (the “Effective
Date”) and is amended as of the 24th day of February 2009 (the “Amendment Date”) between: 
 UNIVERSITY HEALTH NETWORK an Ontario corporation incorporated by special statute under the University Health Network Act, 1997, having a principal office at 190 Elizabeth Street, R. Fraser Elliott Building – Room 1S-417,
Toronto, Ontario, M5G 2C4, Facsimile (416) 977-4765 
 (“UHN”) 
 -AND- 
 MED
BIOGENE INC., a British Columbia corporation, having a principal office at 300 – 2386 East Mall, Gerald McGavin Building, Vancouver, British Columbia, V6T 1Z3, Facsimile (604) 827-5120 
 (“MBI”) 
 Whereas:

 A. UHN owns certain technology developed by UHN researchers Drs. Ming-Sound Tsao and Frances A. Shepherd relating to
messenger RNA (“mRNA”) expression-based methods for prognosing early-stage non-small-cell lung cancer survival (the “Licensed Technology”, as defined herein). 
 B. Pursuant to a Sponsored Research Agreement (the “Sponsored Research Agreement”) between the Parties dated even date
herewith and amended as of the Amendment Date, UHN desires to undertake further research, development and validation of the Licensed Technology in respect of said prognostic mRNA expression-based signatures, with the intellectual property developed
thereunder forming a part of the Licensed Technology hereunder. 
 C. UHN desires to license certain rights in the Licensed
Technology and MBI desires to obtain certain rights to the Licensed Technology. 
 D. MBI and UHN have agreed to enter into an
additional exclusive license agreement (the “Additional Exclusive License Agreement”) and an additional sponsored research agreement (the “Additional Sponsored Research Agreement”) relating to a 15-gene
prognostic mRNA expression-based signature to be used in the clinical management of lung cancers, dated effective as of the Amendment Date. 
 NOW THEREFORE THIS AGREEMENT WITNESSES that in consideration for the mutual promises, representations, covenants and agreements of the Parties contained herein and for other good and valuable
consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties agree as follows. 
 ARTICLE 1 -
INTERPRETATION 
 1.1 Defined Terms. For the purposes of this Agreement, unless the context otherwise requires, the following terms
shall have the respective meanings set out below and grammatical variations of such terms shall have corresponding meanings: 
  

	(a)	“Affiliate” means, with respect to any Person, any Person directly or indirectly controlled by, controlling or under common control with such Person.
For the purposes of this definition, except as otherwise expressly set out in this Agreement, “control” shall mean direct or indirect beneficial ownership of 50% or greater interest in the income of such Person or such other relationship
as, in fact, constitutes actual control; 

	(b)	“Agreement” means this agreement and all schedules attached hereto, and the terms “herein”, “hereunder”, “hereto” and
such similar expressions shall refer to this Agreement; 

  

	(c)	“CLIA” means the Clinical Laboratory Improvement Amendments regulations and program for the regulation in the United States of laboratory testing
administered by the Centers for Medicare & Medicaid Services (CMS); 

  

	(d)	“Clinical Data” means the personal and/or patient-related information and data which may be disclosed by UHN to MBI under this Agreement and/or the
Sponsored Research Agreement; 

  

	(e)	“Confidential Information” of a party means any and all information of and disclosed by a Party and/or any of its Affiliates (a “Disclosing
Party”) which has or will come into the possession or knowledge of the other Party and/or any of its Affiliates (a “Receiving Party”) in connection with or as a result of entering into this Agreement and which is marked as
confidential or is identified as confidential at the time of disclosure, including information concerning the Disclosing Party’s past, present and future business, research and development, technology, customers and suppliers. For the purposes
of this definition, “Confidential Information” may include any and all Intellectual Property, Licensed Technology, product, commercial, research, scientific, customer or market information and analyses or conclusions drawn or derived
therefrom; the Disclosing Party’s raw materials, processes, formulations, analytical procedures, methodologies, products, samples, specimens, functions, Know-how, data, patents, copyrights, trade secrets, processes, techniques, programs,
designs, formulae, marketing, advertising, financial, commercial, sales or programming materials, written materials, compositions, drawings, diagrams, computer programs, studies, work in progress, visual demonstrations, ideas, concepts, and other
data, in oral, written, graphic, electronic, or any other form or medium whatsoever. All Clinical Data shall be considered UHN Confidential Information, save and except for such Clinical Data reasonably required to be included in a manuscript for
acceptance of publication made in accordance with this Agreement and the Sponsored Research Agreement. Information shall not be considered “Confidential Information” to the extent that, when considered as a whole and in the context
disclosed, the information: 

  

	 	(i)	is part of the public domain at the time of disclosure, 

  

	 	(ii)	subsequently becomes part of the public domain through no act or fault of the Receiving Party or its agents or employees, 

  

	 	(iii)	can be demonstrated by the Receiving Party’s written records to have been known or otherwise available to the receiving party prior to the disclosure by the
Disclosing Party, 

  

	 	(iv)	can be demonstrated by the Receiving Party’s written records to have been subsequently provided to the receiving Party, without restriction, by a Third Party who
is not under a duty of confidentiality respecting the information disclosed and who has a legal right to disclose it, 

  

	 	(v)	can be demonstrated by the Receiving Party’s written records was subsequently and independently developed by employees or consultants of the Receiving Party who
had no knowledge of or access to the information disclosed, 

  

	 	(vi)	is required to be disclosed by law or an order of a court, tribunal, or government agency, provided that the Receiving Party gives to the Disclosing Party prompt notice
of the required disclosure in order to allow the Disclosing Party reasonable opportunity to seek a confidentiality order or the like, 

  

	 	(vii)	is reasonably required to be disclosed by MBI in any Patent filings or under CLIA or the FDA regulations, or any successor agencies thereof, or other regulations in the
United States or other jurisdictions, in respect of the submission for, or the receipt of, regulatory approval or clearance of a Licensed Product, or 

  

 2 

	 	(viii)	is identified in writing by the disclosing Party as no longer constituting Confidential Information; 

  

	(f)	“Contract Year” means, during the Term, the initial period commencing on the Effective Date and ending on the expiration of the fourth Quarter Yearly
Period thereafter, and each subsequent twelve month period commencing on the day after the expiration of the foregoing fourth Quarter Yearly Period and on each anniversary thereof. The last Contract Year shall end on the day this Agreement expires,
or is earlier terminated; 

  

	(g)	“Current Market Price” of shares in the capital stock of MBI on any date means the average of the daily closing prices for the 10 consecutive trading
days immediately preceding such date, provided that if the shares are not listed on any stock exchange, the “Current Market Price” shall be determined by the board of directors of MBI acting in good faith; 

  

	(h)	“FDA” means the United States Food and Drug Administration, or any successor agency thereof; 

  

	(i)	“Gross Revenues” means the gross amount invoiced and received by MBI or others on its behalf for all Licensed Products sold or otherwise transferred to
end users of the Licensed Product. Any Licensed Products sold or otherwise transferred in other than an arm’s-length transaction or for other property (e.g. barter) or at less than fair market value shall be deemed invoiced at its fair market
price in such country or sale or transfer; 

  

	(j)	“Including” means including without limitation; 

  

	(k)	“Improvements by MBI” means any and all improvements to the Licensed Technology made by MBI, its employees and consultants, outside of the Research
Program after the Effective Date, which claim priority to or otherwise rest on claims of the Licensed Patents described in and/or listed in Section 1 of Schedule A, as amended from time to time. 

  

	(l)	“Improvements by UHN PI(s)” means any and all improvements to the Licensed Technology developed at UHN by the Principal Investigators (and the UHN
personnel, employees, staff members, students, agents and consultants under their direct supervision) outside of the Research Program after the Effective Date, which claim priority to or otherwise rest on claims of the Licensed Patents described in
and/or listed in Section 1 of Schedule A, as amended from time to time; 

  

	(m)	“Improvements by UHN non-PI(s)” means any and all improvements to the Licensed Technology developed at UHN by UHN personnel other than the Principal
Investigators (and the UHN personnel, employees, staff members, students agents and consultants under their direct supervision) outside of the Research Program after the Effective Date, which claim priority to or otherwise rest on claims of the
Licensed Patents described in and/or listed in Section 1 of Schedule A, as amended from time to time; 

  

	(n)	“Intellectual Property” means inventions, discoveries, written material, compounds, patentable and unpatentable information, Know-how, trade secrets,
copyright, designs, plant breeders’ rights, integrated circuit topographies, ideas (including but not limited to any computer software), formulae, algorithms, concepts, proprietary data, techniques, instructions, processes, expert opinions,
information, Materials, program listings, flow charts, logic diagrams, manuals, specifications, instructions, or any copies of the foregoing in any medium, or the expression thereof; 

  

	(o)	“Intellectual Property Rights” means any proprietary, possessory, use and ownership rights, titles and interests (whether beneficial or legal) of all
kinds whatsoever, in and to any Intellectual Property, including by way of Patents, Patent applications, trade-marks, trademark applications, copyrights, copyright applications, industrial designs, industrial design applications, Know-how and trade
secrets, and all other intellectual and industrial property rights whatsoever and world-wide (whether registered or unregistered and including rights in any application for any of the foregoing); 

  

 3 

	(p)	“Joint Research Program IP” means any and all Intellectual Property conceived or developed with contributions by both UHN and MBI (which includes their
respective personnel, staff members, employees, students, agents and consultants) pursuant to activities conducted in respect of the Research Program under the Sponsored Research Agreement, including, without limitation, the Licensed Patents
described in and/or listed in Section 3 of Schedule A, as amended from time to time. Joint Research Program IP shall not include UHN Other IP; 

  

	(q)	“Know-how” means any information pertaining to a technology which is not disclosed in a patent or published patent application, and includes
trade-secrets; 

  

	(r)	“License” shall have the meaning provided in Section 2.1; 

  

	(s)	“Licensed Field” means the use in respect of mRNA expression-based signatures for the clinical management of lung cancers, and shall specifically
exclude (i) prognostic and/or diagnostic DNA-based assays, approaches and/or methodologies for any application, and (ii) prognostic and/or diagnostic protein-based assays, approaches and/or methodologies for any application;

  

	(t)	“Licensed Patents” means the Patents described in and/or listed in Schedule A, as amended from time to time; 

  

	(u)	“Licensed Product” shall mean: 

  

	 	(i)	any product the making, having made, using, selling, offering for sale or importing of which would, but for the license granted herein, infringe a Valid Claim of one or
more of the Licensed Patents, and 

  

	 	(ii)	any service the provision of which would, but for the license granted herein, infringe a Valid Claim of one or more of the Licensed Patents; 

 

	(v)	“Licensed Technology” means: 

  

	 	(i)	the UHN Existing IP, 

  

	 	(ii)	the UHN Research Program IP, and 

  

	 	(iii)	the Joint Research Program IP, 

 but excluding any Improvements by UHN PI(s) and any Improvements by UHN non-PI(s) and UHN Other IP, unless expressly agreed in writing by the Parties to be included hereunder pursuant to Section 2.3; 
  

	(w)	“Materials” means any materials pertaining to the Licensed Technology which is disclosed and/or provided by UHN to MBI; 

  

	(x)	“Net Revenues” mean Gross Revenues, less: 

  

	 	(i)	credits or allowances, if any, given or made for purchase charge backs, price reductions, returns, rebates, rejections, recall or destruction of spoiled, damaged,
out-dated, returned or otherwise unacceptable product (voluntarily made or requested or made by quantity, trade, an appropriate governmental agency, subdivision or department) on account of or in relation to the invoiced sales price of Licensed
Products, 

  

	 	(ii)	if actually allowed or given: 

  

	 	(A)	allowances and/or incentives, 

  

	 	(B)	price reductions, and 

  

	 	(C)	rebates, 

 on account of or in
relation to the invoiced sales price of Licensed Products, 
  

	 	(iii)	any duty, tax, excise or governmental charge upon or measured by the production, sale, transportation, delivery or use of Licensed Products related to or based upon
sales of Licensed Products (including value added taxes but excluding taxes on net income), and 

  

 4 

	 	(iv)	transportation and handling charges or allowances (freight, postage, shipping and insurance), if any, incurred on account of or in relation to the invoiced sales price
of Licensed Products. 

 “Net Revenues” shall not include any amount for: 
  

	 	(v)	the transfer of free samples of Licensed Product for marketing purposes or on compassionate grounds and, prior to marketing, trial materials, and

  

	 	(vi)	the sale or other transfer of Licensed Product by or between Affiliates unless the receiving party is the end user of the Licensed Product, provided that any subsequent
resale or re-transfer of such Licensed Product to an end user of the Licensed Product shall be included in “Net Revenues.” 

 Net Revenues shall be determined from the books and records of MBI and/or its Affiliates maintained in accordance with Canadian generally accepted accounting principles consistently applied; 

 

	(y)	“Notice” shall have the meaning provided in Section 11.1; 

  

	(z)	“Parties” means UHN and MBI collectively, and “Party” means each individually; 

  

	(aa)	“Patent” shall mean: 

  

	 	(i)	any issued patent or patent application including any provisional patent application or any patent application filed under any international Convention or Treaty,

  

	 	(ii)	all continuations and continuations-in-part applications to the issued patent or patent application set out in Paragraph (i) (solely to the extent such
continuations-in-part applications contain subject matter on which claims issuing obtain the benefit of a priority date of any patent or patent application set out in Paragraph (i)), 

  

	 	(iii)	all divisions, patents of addition, reissues, renewals and extensions of any of the patent, patent application, continuations and continuations-in-part applications set
out in Paragraphs (i) and (ii), and 

  

	 	(iv)	all foreign counterparts of any of the foregoing (including, without limitation, European Supplementary Protection Certificates or its equivalent);

  

	(bb)	“Person” means and includes any individual, corporation, partnership, firm, joint venture, syndicate, association, trust, government body and any other
form of entity or organization; 

  

	(cc)	“Principal Investigator(s)” or “PI(s)” shall mean Drs. Ming-Sound Tsao and/or Frances A. Shepherd in their capacity as a UHN employee
and/or staff member; 

  

	(dd)	“Quarter Yearly Period” means each successive three calendar month period during the Term ending January 31, April 30, July 31
and October 31 of each Contract Year. The first and last Quarter Yearly Periods may be less than three calendar months and will commence on the Effective Date and terminate on the date this Agreement expires or is earlier terminated
respectively; 

  

	(ee)	“Research Program” means the sponsored research relating to the further research, development and validation of the Licensed Technology undertaken by
UHN under the Sponsored Research Agreement; 

  

	(ff)	“Sublicensing Revenue” means all revenues, receipts, monies, milestone payments and research fees (in respect of research fees, only to the extent that
same are in excess of reimbursement for the direct costs of research and development or pursuit of regulatory approval undertaken by MBI or its Affiliates pursuant to a written research or development plan), payments (including amounts received from
the sale of shares in the capital stock of MBI in excess of the Current Market Value for such shares), royalties, license fees and the fair market value of all other consideration collected or received by MBI or its Affiliates whether by way of
cash, or credit or any barter, benefit, advantage, or concession: 

  

	 	(i)	arising from any sublicense agreements relating to any Valid Patent Claims under the Licensed Patents, or 

  

 5 

	 	(ii)	otherwise relating to any Licensed Products (but not including Net Sales); 

  

	(gg)	“Territory” means all countries world-wide; 

  

	(hh)	“Term” has the meaning set out in Section 7.1; 

  

	(ii)	“Third Party” shall mean a Person other than UHN, MBI or their respective Affiliates; 

  

	(jj)	“UHN Existing IP” means UHN’s pre-existing background Intellectual Property relevant to the Research Program, including, without limitation, the
Licensed Patents described in and/or listed in Section 1 of Schedule A, as amended from time to time, and the relevant Clinical Data; 

  

	(kk)	“UHN Other IP” means all Intellectual Property developed by UHN (which includes, without limitation, Principal Investigator(s) and the UHN personnel,
employees, staff members, students agents and consultants under their direct supervision) which is not specifically and solely related to prognostic mRNA expression-based signatures for the clinical management of lung cancers. UHN Other IP shall
include, without limitation, all Intellectual Property related to: 

  

	 	(i)	prognostic and/or diagnostic genetic-based approaches and/or methodologies of general application, 

  

	 	(ii)	prognostic and/or diagnostic DNA-based approaches and/or methodologies for any application, and 

  

	 	(iii)	prognostic and/or diagnostic protein-based approaches and/or methodologies for any application, 

 and UHN Other IP shall exclude prognostic mRNA expression-based signatures for the clinical management of lung cancers; 
  

	(ll)	“UHN Research Program IP” means any and all Intellectual Property conceived or developed solely by UHN (which includes its personnel, staff members,
employees, students, agents and consultants) pursuant to activities conducted specifically in respect of the Research Program under the Sponsored Research Agreement, including, without limitation, the Licensed Patents described in and/or listed in
Section 2 of Schedule A, as amended from time to time. UHN Research Program IP shall not include UHN Other IP; and 

  

	(mm)	“Valid Patent Claim” means, with respect to each country in the Territory: 

  

	 	(i)	a claim of a pending patent application, provided that the patent application has not been pending for longer than ten (10) years after the date from which such
application claims priority, and 

  

	 	(ii)	a claim of an issued, unexpired patent or a claim of an issued, unexpired patent term extended by the European Supplementary Protection Certificate(s) or its
equivalent, 

 that has not been: 
  

	 	(iii)	permanently revoked, held invalid, unpatentable or unenforceable by a final decision of a court or governmental agency of competent jurisdiction, which decision is
unappealable or was not appealed within the time allowed therefor, or 

  

	 	(iv)	admitted in writing to be invalid or unenforceable by the holder(s) by reissue, disclaimer or otherwise. 

 1.2 Sections and Headings. The division of this Agreement into articles, sections and subsections and the insertion of headings are for reference
purposes only and shall not affect the interpretation of this Agreement. Unless otherwise indicated, any reference herein to a particular article, section, subsection or Schedule refers to the specified article, section or subsection of or schedule
to this Agreement. 
  

 6 

 1.3 Number, Gender and Persons. In this Agreement, words importing the singular number shall include
the plural and vice versa, words importing gender shall include all genders and words importing persons shall include individuals, corporations, partnerships, associations, trusts, unincorporated organizations, governmental bodies and other legal or
business entities. 
 1.4 Currency. All monetary amounts in this Agreement are in Canadian funds. 
 1.5 Schedules. The following schedules are annexed to and form part of this Agreement: 
 Schedule A – Licensed Patents 
 1.6 Accounting Principles. Any reference in this Agreement to generally accepted accounting principles refers to generally accepted accounting principles as approved from time to time by the Canadian Institute of Chartered
Accountants or any successor institute. 
 1.7 Best of Knowledge. “To the best of the knowledge” or “to the
knowledge”, unless otherwise qualified hereunder means a statement of the declaring party’s knowledge of the actual facts or circumstances to which such phrase relates without having made any inquiries or investigations in connection with
such facts and circumstances. 
 ARTICLE 2 - GRANT OF LICENSE 
 2.1 License. Subject to the terms and conditions of this Agreement, UHN grants to MBI: 
  

	(a)	in respect of the Licensed Technology (other than the Clinical Data), an exclusive; and 

  

	(b)	in respect of the Clinical Data, a non-exclusive, 

 royalty-bearing license, with the right to grant sublicenses without consent, in any and all its rights in and to the Licensed Technology (including all associated Know-how) for the Licensed Field in the Territory, including to research,
develop, manufacture, have manufactured, use, have used, sell or have sold, offer for sale, import and export the Licensed Technology, and to produce and reproduce work in the Licensed Technology or any part thereof, for the Licensed Field in the
Territory (the “License”). 
 2.2 Retention of Rights. The License granted to MBI under Section 2.1 herein is
subject to, and any licenses to be granted to MBI further to Section 2.3 shall be subject to, UHN’s retention of a non-exclusive, world-wide, fully-paid, royalty-free license to use the Licensed Technology, any Improvements by UHN PI(s)
licensed to MBI and any Improvements by UHN non-PI(s) licensed to MBI (collectively, the “Retained Rights”), solely for research, scholarly publication, educational or other non-commercial use, subject to the Confidential
Information provisions of this Agreement, with the further right to grant sublicenses to the Retained Rights for such research, scholarly publication, educational or other non-commercial use(s) to other not-for-profit research institutions who agree
to be bound by the same obligations, including confidentiality obligations, as apply to UHN in respect of the Retained Rights under this Agreement. 
 2.3 Improvements by UHN. 
  

	(a)	 Improvements by UHN PI(s) In consideration of MBI providing to UHN the payments described in this Agreements, UHN hereby grants to MBI a right
of first negotiation for an exclusive, royalty-bearing license, with the right to grant sublicenses without consent, to any Improvements by UHN PI(s) (including any associated Know-how) for the Licensed Field in the Territory. UHN will provide MBI
with written notice of each Improvement by UHN PI(s) promptly after UHN files a Patent application for such Improvement by UHN PI(s), which notice shall be accompanied by sufficient data and other information to enable MBI to evaluate such
Improvement by UHN PI(s). MBI will have six (6) months after receiving written notice from UHN to provide written notice to UHN of its intent to license said improvement (in this subsection, a “Notice of Intent”). If UHN does
not receive a Notice of Intent under this Subsection 2.3(a) within six (6) months, MBI’s right

  

 7 

	 	 
of first refusal will lapse and UHN will be free to dispose of the Improvement by UHN PI(s) as it sees fit. After the Notice of Intent has been received further to this Subsection 2.3(a), both
Parties shall diligently and in good faith negotiate the addition of such Improvement by UHN PI(s) to the Licensed Technology under this Agreement or the licensing thereof under a separate license agreement. Any such separate license shall be on
terms and conditions that are consistent with other such licenses within the industry and satisfactory to UHN. If the Parties have not agreed on the license agreement within nine (9) months of receipt of the Notice of Intent further to this
Subsection 2.3(a), either Party may, at its option, refer the matter to the dispute resolution mechanism specified in Article 10. 

  

	(b)	Improvements by UHN non-PI(s). 

  

	 	(i)	In consideration of MBI providing to UHN the payments described in this Agreements, UHN hereby grants to MBI a right of first negotiation for an exclusive,
royalty-bearing license, with the right to grant sublicenses without consent, to any Improvements by UHN non-PI(s) (including any associated Know-how) for the Licensed Field in the Territory. UHN will provide MBI with written notice of each
Improvement by UHN non-PI(s) promptly after UHN files a Patent application for such Improvement by UHN non-PI(s), which notice shall be accompanied by sufficient data and other information to enable MBI to evaluate such Improvement by UHN non-PI(s).
MBI will have six (6) months after receiving written notice from UHN to provide written notice to UHN of its intent to license said improvement (in this subsection, a “Notice of Intent”). If UHN does not receive a Notice of
Intent under this Subsection 2.3(b) within six (6) months, MBI’s right of first refusal will lapse and UHN will be free to dispose of the Improvement by UHN non-PI(s) as it sees fit. After the Notice of Intent has been received further to
this Subsection 2.3(b), both Parties shall diligently and in good faith negotiate the addition of such Improvement by UHN non-PI(s) to the Licensed Technology under this Agreement or the licensing thereof under a separate license agreement. Any such
separate license shall be on terms and conditions that are consistent with other such licenses within the industry and satisfactory to UHN. If the Parties have not agreed on the license agreement within nine (9) months of receipt of the Notice
of Intent further to this Subsection 2.3(b), UHN will be free to dispose of the Improvement by UHN non-PI(s) as it sees fit. 

  

	 	(ii)	Each right of first negotiation and each license granted to MBI by UHN in and to any Improvements by UHN non-PI(s) under this Subsection 2.3(b) will be subject to Third
Party Intellectual Property Rights. For each Independent Invention for which MBI has a right of first negotiation, UHN and MBI shall cooperate and work together, prior to any Third Party being granted any interest in the Intellectual Property Rights
in such Improvements by UHN non-PI(s), to review the merits of any claims made by any Third Parties to the Intellectual Property Rights in such Improvements by UHN non-PI(s). For each Improvement by UHN non-PI(s) for which MBI has delivered a Notice
of Intent, and for which no Third Party claim is substantiated, UHN and MBI shall in good faith negotiate a license to MBI for the Intellectual Property Rights in the Improvements by UHN non-PI(s). UHN shall keep MBI apprised of any facts that may
arise from time to time where a Third Party may have or make a claim to Intellectual Property Rights in any Improvements by UHN non-PI(s). If a Third Party makes an unsubstantiated claim to Intellectual Property Rights in an Improvement by UHN
non-PI(s), UHN and MBI shall cooperate on the appropriate course of action to defend against any such claim or challenge, restrain or enjoin any Intellectual Property Rights asserted by the Third Party in UHN’s discretion, acting reasonably,
and in good faith in order to protect MBI’s interests in such Intellectual Property Rights. UHN shall take the lead in discussions with any Third Parties relating to any such claims; provided that, in the unlikely event of litigation, MBI shall
have the right to control any such litigation, including the right to settle any dispute in any manner it deems expedient, and UHN shall reasonably assist MBI in connection therewith. 

  

 8 

 2.4 Improvements by MBI. UHN is granted a perpetual royalty free license to any Improvements by MBI
in the Territory solely for research, scholarly publication, educational or other non-commercial use, subject to the Confidential Information provisions of this Agreement. 
 2.5 Sublicenses. MBI shall have right to grant sublicenses or cross-licenses to any Person, without the consent of, but with notice to, UHN. MBI shall ensure that any such sublicense or
cross-license places obligations on the sublicensee or cross-licensee that are consistent with the terms and conditions of this Agreement. 
 2.6 Commercialization. 
  

	(a)	In the event that the Research Program demonstrates that the Licensed Technology: 

  

	 	(i)	has the requisite accuracy, sensitivity and specificity; and 

  

	 	(ii)	may be implemented in a clinical setting to assist in the clinical management of early-stage non-small-cell lung cancer, 

 both being reasonably required for commercialization of a Licensed Product, MBI shall, at its sole cost, expense and discretion, utilize
commercially reasonable efforts and sound and reasonable business practice and judgment in developing and promoting, marketing, selling and otherwise commercializing one or more Licensed Products in the Territory, including in determining the
countries in the Territory in which it desires to sell the Licensed Product and in obtaining the appropriate regulatory approvals therefor, to meet or cause to be met the market demand for the Licensed Product. 
  

	(b)	MBI agrees that it will utilize sound and reasonable business practice and judgment in determining the countries in the Territory in which it desires to sell the
Licensed Product. MBI or its marketing partner or sublicensees, as the case may be, shall not be in breach of its obligations under this Section 2.6 during any particular period during the Term where it determines utilizing sound and reasonable
business practice and judgment that a decision of a relevant governmental authority in a country relating to the price or reimbursement for a Licensed Product renders the commercial sale of the Licensed Product commercially unviable in the country
during such period. 

  

	(c)	Prior to a first commercial sale of Licensed Product, and within thirty (30) days of a Contract Year anniversary, MBI shall provide UHN with annual reports
summarizing its commercialization activities in respect of Licensed Technology. 

 2.7 FDA Clearance for Diagnostic
Service. MBI shall use commercially reasonable efforts, commencing prior to, on or about the time of commercialization in the United States of a commercial assay incorporating the Licensed Technology as a diagnostic service, to apply for and
receive clearance from the FDA for performing such diagnostic service. 
 2.8 Transfer of Information. Upon request by MBI during the
Term, UHN shall promptly deliver to MBI copies of the Licensed Technology, including UHN’s Know-how therein, in written or other tangible form, together with reasonable assistance in connection therewith. 
 ARTICLE 3 - CONSIDERATION 
 3.1 Initial License Fee. MBI shall pay to UHN an up-front license fee of $[*] upon on execution of this Agreement. 
 3.2
Research Program Success Fees. Subject to Section 9.6 of the Sponsored Research Agreement, MBI shall pay to UHN the following research and development success fees upon Successful Completion of the applicable Phase of the Research
Program and receipt by MBI of the required report as set out in the Sponsored Research Agreement: 
  

	(a)	$[*] upon Successful Completion of Phase 1 of the Research Program; 

  

	*	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted
portions. 

  

 9 

	(b)	$[*] upon Successful Completion of Phase 2 of the Research Program; and 

  

	(c)	$[*] upon Successful Completion of Phase 3 of the Research Program, 

 provided that, in the event that there is a delay in completing a particular Phase of the Research Program caused by no fault of UHN and the time period for completion by UHN of the relevant Phase of the
Research Program for Successful Completion thereof has expired, then MBI shall pay to UHN fifty percent (50%) of the amount owing as if UHN had completed “Successful Completion” thereof, and then upon completion of Successful
Completion thereof MBI shall pay the remaining fifty percent (50%) in full satisfaction of the relevant success fee. 
 “Successful
Completion” and “Phase” shall have the meanings set out in the Sponsored Research Agreement. For greater certainty, in the event that MBI does not suspend or terminate the Sponsored Research Agreement or the Additional
Sponsored Research Agreement, as contemplated in each of those agreements, then UHN shall be eligible for Research Program success fees under both this Agreement and the Additional Exclusive License Agreement. 
 3.3 Milestone Payments. In consideration of the license granted hereunder, MBI shall pay to UHN the following milestone payments: 
  

	(a)	$[*] upon the first commercial sale in the United States of a Licensed Product under CLIA; 

  

	(b)	$[*] upon a first submission to the FDA for regulatory approval in the United States for a Licensed Product; 

  

	(c)	$[*] upon a first regulatory approval by the FDA for a Licensed Product; 

  

	(d)	$[*] upon the first commercial sale of the first FDA-approved Licensed Product; and 

  

	(e)	$[*] in the event that the average commercial sale “price” of said Licensed Product, under CLIA and/or as an FDA-approved Licensed Product, for the first [*]
product sales or service transactions, as the case may be, exceeds $[*]; 

 provided that if MBI does not receive clearance from
the FDA for a commercial assay incorporating the Licensed Technology as a diagnostic service within six (6) years after the Amendment Date, then the milestone payments set out under Subsections 3.3(b), 3.3(c) and 3.3(d) shall be replaced by the
following four (4) milestone payments: 
  

	(f)	$[*] at the end of such sixth (6th) year; 

  

	(g)	$[*] on the first anniversary of the end of such sixth (6th) year; 

  

	(h)	$[*] on the second anniversary of the end of such sixth (6th) year; and 

  

	(i)	$[*] on the third anniversary of the end of such sixth (6th) year; 

 provided that any milestone payments previously paid by MBI to UHN under Subsections 3.3(a) through 3.3(d) shall be credited against any payments owed under Subsection 3.3(f) through 3.3(i). 

3.4 Basic Royalty. In consideration of the license granted hereunder, MBI shall pay to UHN, without duplication, in respect of each Licensed
Product: 
  

	(a)	in each country in the Territory where the Licensed Product sold is covered by one or more Valid Claims within the Licensed Patents, either in the country of
manufacture or in the country of sale, a royalty of [*]% of Net Revenues of such Licensed Product received by MBI and its Affiliates; and 

  

	(b)	in each country in the Territory where there is no Valid Patent Claim either in the country of manufacture or in the country of sale, but Licensed Technology is
necessary to make, have made, use, sell, offer for sale or import the Licensed Product, either in the country of manufacture or in the country of sale, a royalty of [*]% of Net Revenues received by MBI and its Affiliates; 

 

	*	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted
portions. 

  

 10 

 in each of Subsections 3.4(a) and 3.4(b), until the later of either: 
  

	(c)	the date of expiration of the last Valid Patent Claim within the Licensed Patents covering the Licensed Product in the country of manufacture or sale, as applicable; or

  

	(d)	the expiration of 15 years after the first commercial sale of such Licensed Product in the country of sale. 

 After the first commercial sale of a Licensed Product incorporating a Valid Patent Claim under the Licensed Technology in any jurisdiction in the Territory,
the royalties under this Section 3.4 shall be subject to a cumulative minimum payment of $[*] in each Quarter Yearly Period during the Term. For purposes of clarification, no multiple royalties shall be due or payable under this
Section 3.4 because the sale or manufacture of any Licensed Product is or shall be covered by more than one Valid Patent Claim within the Licensed Patents in the country of manufacture and/or the country of sale. 
 3.5 Sublicensing Royalty. In consideration of the license granted hereunder, MBI shall pay to Licensor, without duplication, in respect of any
Licensed Products a royalty of [*]% of Sublicensing Revenue collected or received by MBI until the later of either: 
  

	(a)	the date of expiration of the last Valid Patent Claim within the Licensed Patents covering the Licensed Product in the country of manufacture or sale, as applicable; or

  

	(b)	the expiration of 15 years after first commercial sale of such Licensed Product in the country of sale. 

 For purposes of clarification, no multiple royalties shall be due or payable under this Section 3.5 because the sale or manufacture of any Licensed
Product is or shall be covered by more than one Valid Patent Claim within the Licensed Patents in the country of manufacture and/or the country of sale. 
 3.6 Payments. 
  

	(a)	Payment of the royalty described in Sections 3.4 and 3.5 above shall be made by MBI within sixty (60) days after the end of each Quarter Yearly Period. Each
milestone and royalty payment to be made by MBI hereunder shall be made in cash, by certified cheque payable to the order of “University Health Network” or by bank transfer to the co-ordinates given by UHN to MBI. 

 

	(b)	All amounts payable to UHN under this Agreement shall be payable in Canadian Dollars. Calendar quarterly sales amounts shall be translated from other currencies to
Canadian Dollars by using an average rate of exchange computed using the rate of exchange quoted under foreign exchange in the Wall Street Journal as of the end of the current quarter plus the rate of exchange as of the end of the immediately
preceding quarter and dividing by 2. 

 3.7 Interest. All monies payable to UHN by MBI hereunder and not paid when due bear
interest at the then prime rate of interest quoted by the Bank of Canada plus two (2) percentage points per annum until the date paid to UHN. UHN will be entitled to that interest in addition to any other rights or remedies available to it in
respect to default in payment by MBI. 
 3.8 Withholdings. In the event that MBI is required by any law to withhold and/or make payments
to tax authorities in respect of any payments payable by MBI to UHN under this Agreement, the liability of MBI under this Agreement shall be to that extent satisfied, and such amounts shall be deemed to have been paid to UHN on their due dates,
provided that MBI shall furnish to UHN acceptable evidence of such payments. 
 3.9 Royalty Report. MBI shall prepare a report (the
“Royalty Report”), setting out the Gross Revenues, the number of Products manufactured and services rendered, an itemized statement of all costs and disbursements and the Net Revenues, if any, for the relevant period. For so long as
the Gross Revenues of MBI is less than $10,000 in any consecutive 12 month period, MBI shall prepare one Royalty Report for every 12 month period. If no payments are due for any reporting period, then the Royalty Report shall so state. Once the
Gross Revenues of MBI are at least $10,000 in any consecutive 12 month period, MBI shall prepare a Royalty Report for each Quarter Yearly Period. Royalty Reports are due within thirty (30) days after the end of the reporting period being
reported. 
  

	*	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted
portions. 

  

 11 

 3.10 Complete Records. MBI shall keep true and accurate records and books of account containing all
data reasonably required for the computing of an verification of all payments owed by MBI to UHN hereunder, including records for Gross Revenues, the number of Licensed Products manufactured and services rendered, costs/disbursements, Net Revenues
in accordance with generally accepted accounting principles. Such records shall be maintained by MBI for at least six (6) years from the date of the payment to which such records are relevant. 
 3.11 Inspection of Records. The records specified in this Agreement shall be available for inspection to UHN or its duly appointed auditor for the
sole purpose of verifying payments owed under this Agreement, during normal business hours at the principal place of business of MBI, upon reasonable notice to MBI. The costs of any such inspection shall be borne by UHN unless the report of an
auditor shows that the Royalty Report was understated by more than five percent (5%), in which case the costs of the examination shall be paid by MBI. 
 3.12 Discrepancy in Records. In the event the said inspection conducted under Section 3.11 herein reveals: 
  

	(a)	any underpayment of royalties due to UHN, MBI will promptly pay UHN the full amount of that underpayment together with interest thereon at the rate of interest referred
to in Section 3.7 herein; and 

  

	(b)	any overpayment of royalties paid to UHN, UHN will promptly refund to MBI or credit MBI’s account, at MBI’s discretion, the full amount of that overpayment
together with interest thereon at the rate of interest referred to in Section 3.7 herein. 

 ARTICLE 4 -
WARRANTIES AND COVENANTS 
 4.1 UHN Warranties. UHN represents and warrants to MBI that: 
  

	(a)	UHN is duly incorporated and organized and validly existing under the laws of the Province of Ontario and has all requisite corporate power and authority to enter into
and perform its obligations under this Agreement; and 

  

	(b)	UHN has taken all necessary corporate action, steps and proceedings to approve or authorize, validly and effectively, the execution and delivery of this Agreement and
the performance of its obligations hereunder. 

 4.2 MBI Warranties. MBI represents and warrants to UHN that: 

 

	(a)	MBI is duly incorporated and organized and validly existing under the laws of the Province of British Columbia and has all the requisite corporate power and authority
to enter into and perform its obligations under this Agreement; 

  

	(b)	MBI has taken all necessary corporate action, steps and proceedings to approve or authorize, validly and effectively, the execution and delivery of this Agreement and
the performance of its obligations hereunder; and 

  

	(c)	the execution and delivery of this Agreement by MBI and the performance of its obligations hereunder shall not result in either a breach or violation of any of the
provisions of, or constitute a default under, or conflict with or cause the acceleration of any obligation of MBI under: 

  

	 	(i)	any agreement to which MBI is a party or bound by, 

  

	 	(ii)	any of the terms and provisions of the notice of articles or articles, or resolutions of the board of directors (or any committee thereof), of MBI,

  

	 	(iii)	any judgement, decree, order or award of any court, governmental body or arbitrator having jurisdiction over MBI, 

  

	 	(iv)	any license, permit, approval, consent or authorization held by MBI, or 

  

 12 

	 	(v)	any applicable law, statute, ordinance, regulation or rule. 

 4.3 Limited Warranties. Except as otherwise expressly set out in this Agreement: 
  

	(a)	UHN expressly disclaims any and all implied or express warranties and makes no express or implied warranties of merchantability, safety or fitness for any particular
purpose of the Licensed Technology; 

  

	(b)	UHN does not warrant or represent that issued patents, or pending patent applications will issue, or when issued will be valid, or that the practice of any technical
information or Know-how disclosed to MBI pursuant to this Agreement does not constitute infringement of rights of persons not parties hereto. Notwithstanding the foregoing, UHN warrants that it has not knowingly granted rights essentially similar to
this License to persons not parties hereto; 

  

	(c)	UHN shall not be liable to MBI for any damage, including any direct, indirect, special or consequential damage suffered by MBI resulting from the use of the Licensed
Technology licensed herein. Further, UHN makes no representation that the Licensed Technology licensed herein is free from defect or liability of Intellectual Property infringement; and 

  

	(d)	UHN’s entire liability to MBI for damages or alleged damages hereunder, whether in contract, tort or any other legal theory, is limited to, and will not exceed an
amount equal to the aggregate amount then paid by MBI to UHN under this Agreement and the Sponsored Research Agreement. 

 4.4
MBI Covenants. MBI covenants and agrees for the benefit of UHN that it shall: 
  

	(a)	exercise the License granted herein in accordance with all applicable laws, statutes, ordinances, regulations, guidelines and rules, including, all applicable statutes
and regulations and applicable guidelines set forth by the Canadian Institutes of Health Research (CIHR), National Institutes of Health (NIH) or other governmental agencies where applicable; 

  

	(b)	in respect of Clinical Data, comply with all applicable laws, regulations and governmental guidelines in respect of the protection of personal and/or patient-related
information and data; 

  

	(c)	ensure that all employees, consultants, sublicensees, and any other persons having access to the subject matter of this Agreement are aware of any and all obligations
under this Agreement, including any and all confidentiality obligations, and have agreed to be legally bound by terms substantially similar thereto; 

  

	(d)	cause to be applied to Licensed Products where appropriate any markings required by applicable government statutes and laws to maintain continued validity and
enforcement of Intellectual Property Rights and will confirm to UHN that such markings are required and if so, will confirm that same are being adhered to; 

  

	(e)	include terms and conditions in any agreement with its customers in connection with the Products and/or Services relating to the Licensed Technology limitations of
representations, warranties and conditions, limits of liability and indemnities from its customers and users which extend the benefit of such provisions to UHN; and 

  

	(f)	immediately notify UHN of the development of any Improvements by MBI to the Licensed Technology in order for UHN to use the Improvements by MBI as permitted in
Section 2.4 hereof. 

 ARTICLE 5 - MANAGEMENT OF INTELLECTUAL PROPERTY RIGHTS 
 5.1 Patent Prosecution. 
  

	(a)	Notwithstanding that UHN shall remain the owner of the Licensed Patents, as of the Effective Date, MBI shall assume responsibility for the preparation, filing,
prosecution and maintenance of any Patents for the Licensed Technology, including, without limitation, the Licensed Patents, at its cost and expense, using patent counsel reasonably acceptable to UHN, and UHN shall arrange for the prompt transfer of
such Patent files to MBI, as may the case may be. 

  

 13 

	(b)	UHN shall own and have responsibility for the preparation, filing, prosecution and maintenance of any Patents for the Improvements by UHN, unless and until licensed to
MBI under Section 2.3. 

  

	(c)	MBI shall own and have responsibility for the preparation, filing, prosecution and maintenance of any Patents for the Improvements by MBI. 

  

	(d)	At any time during the Term, MBI, in MBI’s sole discretion, may determine that any particular Patent within the Licensed Patents in any particular country in the
Territory should not be prosecuted or maintained for legal or commercial reasons and, in such event, shall so notify UHN. UHN, at UHN’s cost and expense and in UHN’s sole discretion, may continue prosecution and/or maintenance of any
particular Patent identified in such notice. 

  

	(e)	UHN shall also have the right to identify any process, use or products relating to the Licensed Technology arising out of the Research Program, and/or any jurisdiction
in which, in the opinion of UHN, a patent is necessary, and MBI shall, upon receipt of such request from UHN, take all reasonable steps to cooperate with UHN in the applications and filing of patents, provided that UHN pays all costs of applying
for, registering, and maintaining any such patents in any jurisdiction in which UHN determines that a patent is required. 

 5.2
Cooperation and Notice. 
  

	(a)	Each Party shall cooperate with the other Party fully in the preparation, filing, prosecution and maintenance of any applications and registrations for Intellectual
Property Rights under Article 5 hereof, including executing all papers and instruments required in order to enable either Party to apply for, to prosecute and to maintain applications and registrations in any country. 

  

	(b)	Each Party shall provide to the other prompt notice as to all matters which come to its attention and which may affect the preparation, filing, prosecution or
maintenance of any such applications or registrations, and shall at all times keep the other fully and promptly informed of all developments in the preparation, filing, prosecution and maintenance of any such applications or registrations.

  

	(c)	Each Party shall have the right to comment on all patent applications to be filed by the other Party within the timeframes of the patent filing process and deadlines.
The Parties will endeavour to account for the comments of the other Party where practicable and reasonable to modify such applications. 

 5.3 Infringement. If any infringement or threatened infringement of the Intellectual Property Rights under this Agreement is perceived by UHN or MBI, the said Party will immediately notify the other Party giving particulars thereof.
The Parties shall co-operate fully in the enforcement of any Intellectual Property Rights. MBI shall have carriage and ultimate authority over the commencement, conduct and settlement of any infringement action against any alleged Third Party. MBI
shall be responsible for all reasonable costs, including legal fees, disbursements and awards by the Court against UHN or MBI pertaining to the enforcement of any Intellectual Property Rights. Any monies awarded to UHN as result of any action or
settlement shall first go to reimburse MBI for the costs. Any remainder monies shall be divided equally between UHN and MBI. 
 5.4 Third
Party Claims of Infringement. 
 In the event that any Third Party brings a claim against MBI or UHN or any of their respective Affiliates
that the manufacture, use, sale, distribution, marketing or importation of a Licensed Product infringes rights in Intellectual Property owned or otherwise controlled by such Third Party (an “Infringement Suit”), the following shall
apply: 
  

	(a)	the Party receiving a claim, or learns of the threat of such a claim, shall give the other Party prompt written notice detailing as many facts as possible concerning
the claim; 

  

 14 

	(b)	MBI, in its sole discretion, shall have the first right, but not an obligation, to defend against the Infringement Suit; 

  

	(c)	if MBI does not take steps to defend against the Infringement Suit within 90 days after the date that notice thereof was received from or delivered to UHN, UHN may take
such legally permissible action as it deems necessary or appropriate to defend against the Infringement Suit, but shall not be obligated to do so; 

  

	(d)	the Party defending against the Infringement Suit (in this section, the “Litigating Party”) shall have the right to control such litigation and shall
bear all legal expenses (including court costs and legal fees), but it shall have no right to settle any dispute in any manner which would abridge the rights of the other Party under this Agreement. By way of example and not by way of limitation,
neither Party may stipulate or admit to the invalidity or unenforceability of any Intellectual Property Rights relating to the Licensed Technology. Before any action is taken by either Party which could abridge the rights of the other Party
hereunder, the parties agree to, in good faith, consult with each other with a goal of adopting a mutually satisfactory position; 

  

	(e)	the Litigating Party shall keep the other Party fully informed of the actions and positions taken or proposed to be taken by the Litigating Party and the actions and
positions taken by all other parties to such litigation; and 

  

	(f)	in the event that MBI defends against the Infringement Suit, UHN may elect to participate formally in the Infringement Suit to the extent that the court may permit,
provided that any additional expenses generated by UHN’s formal participation shall be paid by UHN. 

 5.5 Infringement by
Third Parties. 
 In the event that either Party reasonably believes that a Third Party is or may be infringing, encroaching or violating any
of the Licensed Patents, then such Party shall promptly notify the other Party in writing of such infringement, encroachment or violation, and the following shall apply: 
  

	(a)	in the event of any infringement, encroachment or violation of any of the Licensed Patents in the Territory: 

  

	 	(i)	MBI, in its sole discretion, shall have the first right, but not an obligation, to take or not take whatever action it believes appropriate, and

  

	 	(ii)	if MBI does not commence action directed toward restraining or enjoining such infringement within 90 days after the date that notice thereof was received from or
delivered to UHN, UHN may take such legally permissible action as it deems necessary or appropriate to enforce such Licensed Patents and restrain such infringement; 

  

	(b)	the Party taking action against an alleged infringer shall have the right to control such action and shall bear all legal expenses (including court costs and legal
fees), but it shall have no right to settle any dispute in any manner which would abridge the reserved rights of the other Party under this Agreement. By way of example and not by way of limitation, neither party may stipulate or admit to the
invalidity or unenforceability of any Intellectual Property Rights relating to the Licensed Technology. Before any action is taken by either Party which could abridge the rights of the other Party hereunder, the Parties agree to consult, in good
faith, with a goal of adopting a mutually satisfactory position; and 

  

	(c)	the Party taking action shall keep the other Party fully informed of the actions and positions taken or proposed to be taken by it and the actions and positions taken
by all other parties to such litigation. 

 5.6 No Challenges. Neither Party shall challenge the validity of any of the
other Party’s Intellectual Property Rights under this Agreement. 
  

 15 

 ARTICLE 6 - CONFIDENTIAL INFORMATION 
 6.1 Confidentiality. It is contemplated that in the course of the performance of this Agreement each Party may, from time to time, disclose
Confidential Information to the other. Each Party agrees that it shall take all proper measures, and at least the same measures as it takes in respect of its own Confidential Information, to keep and use in strict confidence all Confidential
Information of the other Party and to not, without the prior written consent of the other Party, disclose any such Confidential Information to any Person other than its Affiliates, corporate counsel, employees, sub-licensees, distributors and
contractors who are under an obligation of confidentiality on terms substantially similar to those set out in this Agreement, who have been informed of the confidential nature of the Confidential Information and as is reasonably required for the
development and commercialization of the Licensed Technology under this Agreement. Neither Party will use or disclose to any other Person any of the Confidential Information except as expressly permitted hereunder. 
 6.2 Disclosure to Advisors. Notwithstanding the confidentiality obligations herein, each Party shall be permitted to disclose the terms of this
Agreement and information relating to the Licensed Technology, without the prior written consent of the other Party, to advisors, shareholders, investors, potential investors, underwriters and others on a need to know basis under circumstances that
reasonably ensure the confidentiality thereof, or to the extent required by law. 
 6.3 Ownership of Confidential Information. All
Confidential Information disclosed by one party to the other shall remain the Intellectual Property of the disclosing party. 
 6.4
Publicity; Use of Names. 
  

	(a)	Neither Party shall (i) use the name, trade-mark or trade-name of the other Party in connection with any public statements or disclosures, or the marketing or
advertising of any Licensed Products, or (ii) issue any press release, public announcement or any disclosure in respect of this Agreement and the Sponsored Research Agreement and any matter associated therewith, without the prior consent of the
other Party, not to be unreasonably withheld. At the request of UHN or MBI respectively, MBI or UHN shall acknowledge the contribution and ownership of UHN and/or MBI to the Licensed Technology, Improvements by UHN PI(s), Improvements by UHN
non-PI(s) or Improvements by MBI, as the case may be. 

  

	(b)	Notwithstanding the foregoing, each Party shall have a right to issue press releases, public announcements or publications, without consent of (but with notice to) the
other Party to the extent that information in any such press release, public announcement or publication has been previously made public or released or to the extent as may be legally required by, for example, the rules and regulations of the
Canadian provincial securities regulators or similar federal, provincial, state or foreign authorities, as determined in good faith by the disclosing Party. 

 6.5 Publication. Neither Party shall publish or provide public disclosure of any invention related to the Licensed Technology that is not the subject of a filed patent application without at least
thirty (30) days prior written notice of such planned publication or disclosure sent to the other Party. In the event any such dissemination is determined by the other Party to be detrimental to its Intellectual Property position, the
disseminating Party shall delay such publication for a period sufficient, but in no event greater than an additional sixty (60) days, to allow the other Party to take the steps necessary to protect such Intellectual Property, including the
filing of any Patent applications and/or deletion of the other party’s Confidential Information. 
 6.6 Duration of Obligation.
Unless otherwise agreed by the Parties in writing, the obligations of the Parties relating to Confidential Information set out in this Article 6 shall survive the expiration or termination of this Agreement for a period of seven (7) years.

  

 16 

 ARTICLE 7 - TERMINATION 
 7.1 Term. Except as otherwise specifically provided for herein or mutually agreed to by the Parties, this Agreement and all the rights and obligations hereunder shall remain in full force and
effect until the expiration of the last Valid Patent Claim under the last Licensed Patent (the “Term”). Upon expiration of the Term, MBI shall have a fully paid, royalty-free right to make, have made, use, have used, sell, have
sold, offer for sale and import Licensed Products without further obligation to UHN. 
 7.2 Events of Termination. This Agreement shall
terminate: 
  

	(a)	at least one (1) day prior to the occurrence of any of the following events: 

  

	 	(i)	MBI files a voluntary petition in bankruptcy or insolvency or shall petition for reorganization under any bankruptcy law, or makes a general assignment for the benefit
of creditors, or otherwise acknowledges insolvency or is adjudged bankrupt, 

  

	 	(ii)	MBI shall consent to an involuntary petition in bankruptcy or if a receiving order is given against it under the Bankruptcy and Insolvency Act (or such other equivalent
Act in the respective jurisdiction), or 

  

	 	(iii)	the appointment of a receiver or other similar representative for MBI by a court of competent jurisdiction; 

  

	(b)	at the discretion of UHN, UHN can immediately effect termination of this Agreement upon written notice to MBI, if MBI materially breaches any of its obligations under
this Agreement including, without limitation, payment of royalties as required under Section 3.1 and failure to commercialize as required under Section 2.6, and fails to, refuses to, or cannot remedy the breach within thirty (30) days
after being given written notice thereof by UHN in accordance with Section 11.1 hereof; 

  

	(c)	at the discretion of MBI, MBI may terminate this Agreement for convenience on thirty (30) days prior written notice to UHN; 

  

	(d)	at any time by mutual consent of the Parties in writing; 

  

	(e)	in the event of termination of the License under Subsection 7.5(c); or 

  

	(f)	upon expiration of the Term as defined in Section 7.1. 

 7.3 Obligations on Insolvency. In the event that this Agreement is terminated for insolvency as described in Subsection 7.2(a), the License and any sublicenses or cross-licenses granted in
accordance with this Agreement will be automatically terminated, and all rights of use of the Licensed Technology and Intellectual Property granted by UHN to MBI, or granted by MBI by way of sublicenses to sublicensees or cross-licenses to
cross-licensees, shall revert to UHN. 
 7.4 Effect of Termination. In the event of early termination of this Agreement: 
  

	(a)	MBI shall cease and desist any use of the subject matter licensed under this Agreement and within thirty (30) days upon the request of UHN and in its sole
discretion, destroy or return to UHN all of UHN’s property, including all Licensed Technology and Confidential Information belonging to UHN (including Clinical Data), and cease to make, use, sell, or reproduce any or otherwise benefit from the
Licensed Technology or UHN improvements; 

  

	(b)	MBI shall within thirty (30) days after the date of termination, pay to UHN all outstanding payments pursuant to Article 3 hereunder; 

  

	(c)	all sublicenses or cross-licenses granted by MBI shall terminate; 

  

	(d)	each Party shall take all necessary steps in a prudent business manner to effect the orderly termination of this Agreement; and 

  

 17 

	(e)	MBI, and any sublicensees or cross-licensees, may continue to sell any existing stock of any Licensed Products manufactured or services offered under License and pay to
UHN royalties according to Article 3 herein. 

 7.5 Effect of Termination of Sponsored Research Agreement. 
  

	(a)	Subject to termination of the License under Subsection 7.5(c), in the event of the termination of the Sponsored Research Agreement: 

  

	 	(i)	by MBI for any reason after the payment by MBI to UHN of the “R&D Success Fee #1” (as described in the Sponsored Research Agreement), whether or not due
and payable; or 

  

	 	(ii)	by MBI at any time for UHN’s failure to successfully complete Phase I, II or III of the Research Program; or 

  

	 	(iii)	by MBI at any time due to a material breach of the Sponsored Research Agreement by UHN that remains uncured by UHN thirty (30) days after the delivery of notice of
such breach provided by MBI to UHN; or 

  

	 	(iv)	by UHN at any time for any reason not described in Subsection 7.5(b) or (c) below, 

 then all licenses granted under this Agreement, and sublicenses or cross-licenses granted thereupon by MBI, shall survive. 
  

	(b)	In the event of the termination of the Sponsored Research Agreement by UHN: 

  

	 	(i)	prior to the completion of Phase I of the Research Program due to a material breach of the Sponsored Research Agreement by MBI that remains uncured by MBI thirty
(30) days after the delivery of notice of such breach provided by UHN to MBI; or 

  

	 	(ii)	after the successful completion of Phase I of the Research Program due to MBI’s material breach of the Sponsored Research Agreement for failure to pay to UHN any
payment owed to UHN by MBI under the Sponsored Research Agreement, if due and payable, where such breach remains uncured by MBI ninety (90) days after the delivery of notice of such breach provided by UHN to MBI, 

 then all licenses granted under this Agreement, and sublicenses or cross-licenses granted thereupon by MBI, shall terminate. 
  

	(c)	If, pursuant to Section 9.6 of the Sponsored Research Agreement, MBI suspends the work under the Sponsored Research Agreement or terminates the Sponsored Research
Agreement, and: 

  

	 	(i)	the work remains suspended for a period of four (4) years after the date of suspension thereof or four (4) years have elapsed after the date of the
termination of the Sponsored Research Agreement, as the case may be; or 

  

	 	(ii)	MBI breaches its obligations under Subsection 5.1(a), and materially impairs the scope of patent coverage of the Licensed Patents under the Licensed Technology for the
uses contemplated under this Agreement and fails to cure such breach; 

 then all licenses granted under this
Agreement, and sublicenses or cross-licenses granted thereupon by MBI, shall terminate. 
 7.6 Survival. The Parties agree the provisions
of Article 1, Article 4, Article 6, Article 7, Article 8, Article 9, Article 10, Article 11 and Article 12 in their entirety and Sections 3.2 through 3.12, and 5.6 shall remain in force and effect after the expiration or earlier termination of this
Agreement, until such time as the Parties mutually agree to the release of the obligations contained therein. 
  

 18 

 ARTICLE 8 - INDEMNIFICATION 
 8.1 Indemnification. MBI for and in consideration of and as a condition to the granting of the License, agrees to indemnify, save harmless, and
defend UHN and its directors, officers, researchers, inventors, employees, students and agents, against any and all claims, suits, losses, damages, costs, fees, and expenses (including reasonable legal expenses), resulting from and arising out of
the exercise by MBI of its rights under this Agreement including, but not limited to, claims arising from: 
  

	(a)	any product liability; 

  

	(b)	Intellectual Property infringement or alleged infringement claims; 

  

	(c)	any damages, losses, or liabilities, whatsoever with respect to death or injury to any person and damage to any property therefrom; 

  

	(d)	the manufacture, design, distribution, offer for sale, of Licensed Products; 

  

	(e)	materials, processes, information or Licensed Technology produced in the course of or used in the results of any subject matter arising under this Agreement;

 except to the extent caused by the negligence or wilful misconduct of UHN or any of the indemnified parties. 
 ARTICLE 9 - INSURANCE 
 9.1
MBI Insurance. No later than thirty (30) days prior to the first use of any Licensed Product in the clinical management of human disease, MBI, at MBI’s expense, shall obtain and maintain appropriate general liability and product
liability insurance for diagnostic and prognostic products (the “MBI Insurance”) at an overall level, incident level, and deductible amount as are standard in the industry at such time naming both MBI and UHN as co-insured. MBI
shall provide to UHN a Certificate of Insurance evidencing compliance with this provision within thirty (30) days prior to such first use and, in no event, shall MBI use any Licensed Product in humans prior to the delivery to UHN of the
Certificate of Insurance. MBI shall, at its own expense, obtain and maintain, from the date required by this section until the end of the Term and for a period of six (6) years thereafter, MBI Insurance. 
 9.2 Sublicensees Insurance. MBI shall ensure that all approved sublicensees or cross-licensees, at the sublicensees’, cross-licensees’ or
MBI’s expense, obtain and maintain appropriate liability insurance at a level commensurate with MBI Insurance, naming both MBI and UHN as co-insured. MBI shall provide to UHN a Certificate of Insurance evidencing compliance with this provision,
within thirty (30) days prior to the first use of the Licensed Product in humans under any sublicense or cross-license agreement. MBI shall ensure that in no event, shall the sublicensee or cross-licensee use the Licensed Product in humans
under this or any sublicense or cross-license agreement prior to the delivery to UHN of the Certificate of Insurance. MBI shall ensure that sublicensees or cross-licensees, as the case may be and at no expense to UHN, obtain and maintain, from the
date required in by this section until the end of the Term and for a period of six (6) years thereafter, a policy of appropriate liability insurance at a level commensurate with MBI Insurance. 
 9.3 Qualified Insurance. All insurance policies required in accordance with this Article 9 shall be obtained from a qualified insurance company
licensed to do business in the jurisdictions governed by this Agreement. 
 9.4 Notice. All insurance policies required in accordance
with this Article 9 shall provide for fifteen (15) business days written notice by the insurer to MBI and UHN by registered or certified mail in the event of any modification, cancellation or termination of such insurance policy. 
 9.5 Copy of Policy. MBI shall, on written request, provide UHN with a copy of the insurance policy in force at the time of the request and this
provision shall survive the termination or expiration of this Agreement. 
  

 19 

 9.6 Incomplete Insurance. In the event MBI is unable to obtain the insurance coverage required by
this Article, or if any portion of MBI Insurance or other required coverage is cancelled and not immediately replaced, MBI shall promptly inform UHN and UHN may at its sole option maintain such insurance as it reasonably considers necessary, at the
expense of MBI. If UHN is unable or unwilling to secure such insurance as it reasonably considers necessary and MBI continues to use the Licensed Technology in humans, then UHN shall be free to terminate this Agreement in accordance with
Section 7.2(b) hereof. 
 ARTICLE 10 - DISPUTE RESOLUTION 
 10.1 Dispute Resolution. In the event of any dispute, controversy or claim among the Parties arising out of or in connection with this Agreement, or
the breach thereof, or in respect of any defined legal relationship associated therewith or derived therefrom, the Parties agree to resolve the dispute in accordance with the following procedures outlined in this Article 10, subject to Subsection
10.5(d). 
 10.2 Good Faith Negotiations. A Party may notify the other Party in writing that a dispute has arisen. The Parties will, in
the first instance, attempt to resolve the dispute, controversy, claim or allegation of breach by entering into good faith negotiations. The Parties shall meet to attempt, in good faith, to resolve the dispute by negotiation, either directly or
through the assistance of such advisors as they may engage. If, within seven (7) days, the Parties do not reach agreement on the resolution of the dispute, the Parties agree to proceed to mediation as set out in Section 10.3 below.

 10.3 Mediation. Subject to Section 10.2, the Parties shall mediate their dispute before a mediator who is a member of
Ontario’s Mandatory Mediation Program Roster of mediators having appropriate experience in the biopharmaceutical industry. If the Parties fail to agree on a mediator within fourteen (14) days after the decision to proceed to mediation,
either Party may apply to a court of competent jurisdiction to appoint an qualified mediator having appropriate experience in the biopharmaceutical industry. Mediation shall be carried out by the mediator within twenty-one (21) days of the
mediator’s appointment. 
 10.4 Arbitration. 
  

	(a)	Subject to Sections 10.2 and 10.3, if the Parties fail to resolve their dispute within seven (7) days of the start of the mediation, the Parties will appoint
an arbitrator having appropriate experience in the biopharmaceutical industry who will conduct an arbitration of the dispute. If the Parties cannot agree on a mutually acceptable arbitrator within seven (7) days of the decision to proceed to
arbitration, either Party may apply to a court of competent jurisdiction to appoint an qualified arbitrator having appropriate experience in the biopharmaceutical industry. The arbitration shall be conducted in accordance with the Arbitration
Act, 1991 (Ontario) and the arbitrator shall also be empowered to hear injunctive proceedings in accordance therewith. 

  

	(b)	Notwithstanding Section 10.5 below, the arbitrator may include in its award an order as to the payment of the costs of the proceedings and reasonable counsel fees.
Any Party ordered to pay costs may avail itself of any procedure for the taxing of costs, provided, however, that the Parties specifically agreed that the officer taxing such costs need not be bound by any statutory scale of costs.

  

	(c)	The arbitrator will make its decision in writing within fifteen (15) days of the hearing and, unless the Parties otherwise agree, the arbitrator’s reasons
will be set out in the award. The award shall be final and binding on the Parties and shall not be subject to any appeal although either Party may request clarification of the award and the arbitrator’s reasons. 

  

	(d)	The Parties consent to the award of the arbitrator being entered in any court having jurisdiction for the purposes of enforcement. In addition, if it appears to any
Party that the arbitrator lacks the power to give effective interim relief, such Party may apply to any appropriate court for such relief. 

  

	(e)	All matters in dispute, all claims, submissions, evidence and findings, and the award itself shall be kept confidential by the arbitrator, and no information regarding
any of the foregoing will be released to any Third Party or otherwise made public without the written consent of the Parties, except as otherwise contemplated herein and except for such information which is not Confidential Information.

  

 20 

	(f)	The Parties may with mutual consent, expand or abridge the time periods provided for in this Article 10. 

 10.5 General. 
  

	(a)	The expenses of the mediation or arbitration shall be borne equally by the Parties. Notwithstanding the foregoing, the mediator or arbitrator may include in his or her
award an order as to the payment of the costs of the proceedings and reasonable counsel or other advisor fees. Any Party ordered to pay costs may avail itself of any procedure for the taxing of costs; provided, however, that the Parties specifically
agree that the officer taxing such costs need not be bound by any statutory scale of costs. 

  

	(b)	All meetings and hearings will be in private unless the Parties otherwise agree. 

  

	(c)	Any Party may be represented at any meetings or hearings by legal counsel or any other advisor. 

  

	(d)	Notwithstanding this Article 10: 

  

	 	(i)	disputes relating to termination under Section 7.2, and/or disputes for inadequate insurance under Article 9 shall not be subject to Article 10;

  

	 	(ii)	either Party shall be free to submit any dispute relating to Intellectual Property, including under Paragraph 7.5(c)(ii), to any court having jurisdiction over the
Parties and the subject matter of the dispute and to seek such relief and remedies as are available in that court; and 

  

	 	(iii)	for disputes relating to the compliance by MBI (or its marketing partner or sublicensee, as the case may be) with the commercialization requirements under
Section 2.6, the evaluation process set out in Schedule B shall apply. 

 ARTICLE 11 - NOTICE 

 11.1 Notice. All Notices which are required or permitted to be given hereunder including judicial payment notices must be in writing.
All such Notices must be sent as follows: 
 To UHN: 
 University Health Network 
 101 College Street – Suite 150 
 Heritage Building – MaRS Centre 
 Toronto, Ontario 
 M5G 1L7 
 Telephone: (416) 581-7410 
 Facsimile: (416) 977-4765 
  

	 	Attention:	Brian H. Barber, PhD, 

	 	            	Director, Technology Development & Commercialization 

 To MBI: 
 Med BioGene Inc. 
 #300 – 2386 East Mall 
 Gerald McGavin Building 
 Vancouver, British Columbia 
 V6T 1Z3 
  

 21 

 Telephone: (604) 827-5100 
 Facsimile: (604) 827-5120 
  

	 	Attention:	Erinn B. Broshko 

	 	            	Chief Executive Officer 

 or to such other
address as the recipient may have designated by Notice given in accordance with this Article 11. Any such Notice may be delivered by hand, by registered mail, or sent by facsimile and will be deemed to have been delivered on the date of delivery if
delivered by hand, five (5) days after mailing if sent by registered mail, or on the first business day following the date of sending, if sent by facsimile. 
 ARTICLE 12 - GENERAL 
 12.1 Entire Agreement. The Parties hereto acknowledge that
this Agreement and its schedules, together with the Sponsored Research Agreement, set forth the entire agreement and understanding of the Parties hereto as to the subject matter hereof, and supersedes all prior discussions, agreements and writings
in respect hereto. 
 12.2 General Assurances. The Parties hereto agree to do all such reasonable things and to execute such instruments
and documents as may be reasonably necessary or desirable in order to carry out the provisions and intent of this Agreement. 
 12.3 Enure to
Benefit. This Agreement shall enure to the benefit of and be binding upon the respective Parties hereto and, where the context admits or requires, their respective permitted successors or assigns. 
 12.4 Assignment and Payment of License Transfer Fee. MBI may only assign the License to a Third Party: 
  

	(a)	with the prior written consent of UHN, which consent will not unreasonably be withheld; or 

  

	(b)	in conjunction with the sale, transfer or other disposition of: (i) all or substantially all of MBI’s business to a Third Party; or (ii) that part of
MBI’s business encompassing or otherwise associated with the development and commercialization of the Licensed Technology, which in either case MBI shall pay to UHN an amount equal to [*]% of the amount received (or in the event that the
consideration received by MBI is in the form of securities, the cash equivalent of such securities) by MBI in respect of such sale, to a maximum received by MBI of $[*], such payment to be made by MBI within thirty (30) days of the closing of
the sale. 

 12.5 No Joint Venture. Each Party is and will remain at all times independent of each other. The Parties are
not and shall not be considered to be joint venturers, partners or agents of each other and neither of them shall have the power to bind or obligate the other except as set forth in this Agreement. The Parties mutually covenant and agree that
neither shall they, in any way, incur any contractual or other obligation in the name of the other, nor shall they have liability for any debts incurred by the other. No representation will be made or acts taken by any of the Parties which could
establish any apparent relationship of agency, joint venture, partnership or employment. 
 12.6 Waiver. No amendment, supplement or
waiver of any provision of this Agreement shall be binding on any Party unless consented to in writing by such Party. No waiver of any provision of this Agreement shall constitute a waiver of any other provision, nor shall any waiver constitute a
continuing waiver unless otherwise expressly provided. Further, no failure or delay by any Party in exercising any right or remedy shall operate as a waiver thereof, nor shall any single or partial exercise or waiver of any right or remedy preclude
its further exercise or the exercise of any other right or remedy. 
 12.7 Time of the Essence. Time is of the essence in this Agreement
and of each and every term and condition hereof. 
  

	*	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted
portions. 

  

 22 

 12.8 Joint Preparation. This Agreement shall be deemed to be jointly prepared by the Parties, and any
ambiguity herein shall not be construed for or against any party. 
 12.9 Governing Law. This Agreement shall be governed by the laws of
the Province of Ontario and the laws of Canada and shall be treated as an Ontario contract. Subject to Article 10, the Parties irrevocably and unconditionally submit to the non-exclusive jurisdiction the courts of the Province of Ontario and all
courts competent to hear appeals therefrom in connection with any matters arising under this Agreement. 
 12.10 Severability of
Provisions. In the event that any provisions of this Agreement are determined to be invalid or unenforceable by a court of competent jurisdiction in any jurisdiction, the remainder of the Agreement shall remain in full force and effect without
said provision in said jurisdiction and such determination shall not affect the validity or enforceability of such provision or the Agreement in any other jurisdiction. The Parties shall in good faith negotiate a substitute clause for any provision
declared invalid or unenforceable, which shall most nearly approximate the intent of the Parties in entering this Agreement. 
 12.11 Force
Majeure. In the event that any one of the Parties is prevented from fulfilling any of its obligations herein by acts of God, war, strikes, riots, storms, fires, governmental orders or restrictions or any other cause beyond its control, the
payment of royalties, or the applicable pro rata portion thereof, shall be suspended during the full period of any such prevention, but payment of royalties which has accrued for payment prior to, or after such cause shall not be excused. 

 12.12 Counterparts and Facsimile. This Agreement may be executed in counterparts and by facsimile each of which shall be deemed an
original but all of which together shall constitute one and the same instrument. 
 IN WITNESS WHEREOF, MBI and UHN have executed this Agreement
through their duly authorized representatives as of the Effective Date. 
  

					
	UNIVERSITY HEALTH NETWORK
		
	Per:	 	/s/ DR. CHRISTOPHER J. PAIGE
		 	Name:	 	Dr. Christopher J. Paige
		 	Title:	 	Vice President Research
	
	MED BIOGENE INC.
		
	Per:	 	/s/ ERINN B. BROSHKO
		 	Name:	 	Erinn B. Broshko
		 	Title:	 	Chief Executive Officer

  

 23 

 SCHEDULE A 
 Licensed Patents 
  

	1.	UHN Existing Patents and Patent Applications 

 Patent family entitled: “Materials and Methods for Prognosing Lung Cancer Survival” ; M.-S. Tsao et al (inventors), including: 
  

	 	(a)	US Prov. Appln. No. 60/865960 (filed Nov. 15, 2006); 

  

	 	(b)	US Appln. No. 11/940707 (filed Nov. 15, 2007); and 

  

	 	(c)	PCT Appl. No. PCT/CA2007/002039 (filed Nov. 15, 2007). 

  

	2.	UHN Research Program Patents 

 UHN Research Program Patents are to be added during the term of the Sponsored Research Agreement. 
  

	3.	Joint Research Program Patents 

 Joint Research Program Patents are to be added during the term of the Sponsored Research Agreement. 
  

	4.	Continuations, Divisionals, Renewals, Extensions 

 For greater certainty, the Licensed Patents shall include: 
  

	 	(a)	any issued patent or patent application (including any provisional patent application or any patent application filed under any international Convention or Treaty)
described or listed in this Schedule A; 

  

	 	(b)	all continuations and continuations-in-part applications to the issued patent or patent application described in Paragraph 4(a) of this Schedule A (solely to the extent
such continuations-in-part applications contain subject matter on which claims issuing obtain the benefit of a priority date of any patent or patent application described in Paragraph 4(a) of this Schedule A); 

  

	 	(c)	all divisions, patents of addition, reissues, renewals and extensions of any of the patent, patent application, continuations and continuations-in-part applications set
out in Paragraphs 4(a) and 4(b) of this Schedule A; 

  

	 	(d)	all regular utility patent applications or patent applications filed under any international Convention or Treaty on the basis of any patent application(s) described or
listed in this Schedule A; and 

  

	 	(e)	all foreign counterparts of any of the foregoing (including, without limitation, European Supplementary Protection Certificates or its equivalent).

 SCHEDULE B 
 Evaluation Process 
 Evaluation of Commercialization Activities.

 1. Each party shall select a mutually acceptable person as an independent evaluator having appropriate experience in the biopharmaceutical
industry (each an “Evaluator”) and the two selected Evaluators shall select a mutually acceptable third Evaluator having appropriate experience in the biopharmaceutical industry, to conduct the evaluation set forth in Section 2
of this Schedule B. If the parties cannot agree on the choice of Evaluators, either Party may apply to a court of competent jurisdiction to appoint an qualified Evaluator having appropriate experience in the biopharmaceutical industry. 

2. Unless the parties mutually agree otherwise, the following rules and procedures shall govern the conduct of the parties and the Evaluators before and
during the investigation by the Evaluators: 
 (a) within 30 days after the selection of the Evaluators, MBI shall provide to the Evaluators and
UHN a written summary of its position. Upon receipt of MBI’s summary, UHN shall have 15 days to prepare and submit to MBI and the Evaluators its own summary in reply to the summary submitted by MBI; and 
 (b) on receipt of the summaries and any other documents, statements or records submitted by the parties, the Evaluators shall have 30 days within which to
conduct such further inquiries as the Evaluators may deem necessary for the purpose of reviewing the efforts made by MBI with respect to the commercialization of the Licensed Products in compliance with the requirements of Section 2.6.

 For the purpose of conducting such an inquiry, the Evaluators shall have the right to: 
 (iii) require either party to disclose any further documents or records which the Evaluators consider to be relevant; 
 (iv) interview or question either orally (or by way of written questions) one or more representatives of either party on issues deemed to be relevant by the
Evaluators; 
  

	(v)	make an “on site” inspection of MBI’s facilities; and 

 (vi) obtain if necessary, the assistance of an independent expert to provide technical information with respect to any area in which the Evaluators do not have a specific expertise. 
 3. The Evaluators shall within 30 days after starting the inquiry, prepare a report setting out the Evaluators’ findings and conclusions as to whether
or not MBI is in breach of Section 2.6. If the Evaluators determine that MBI is in breach, then the Evaluators shall specify in the report the Evaluators’ conclusions as to what additional measures may be required to achieve compliance
with Section 2.6, and MBI shall thereafter make the efforts so specified. If MBI fails to make such efforts, after notice of termination for breach provided in accordance with the terms of Section 7.2(b), then UHN’s sole remedy for
MBI’ failure to make the efforts specified in Section 2.6 shall be that this Agreement may be terminated in accordance with Section 7.2(b).Amended and Restated Sponsored Research Agreement

 EXHIBIT 10.9 
 AMENDED AND RESTATED 
 SPONSORED RESEARCH AGREEMENT 
 This amended and restated agreement (this “Agreement”) is made effective as of the 14th day of April 2008 (the “Effective
Date”) and is amended as of the 24th day of February 2009 (the “Amendment Date”) between: 
 UNIVERSITY HEALTH NETWORK an Ontario corporation incorporated by special statute under the University Health Network Act, 1997, having a principal office at 190 Elizabeth Street, R. Fraser Elliott Building - Room 1S-417,
Toronto, Ontario, M5G 2C4, Facsimile (416) 977-4765 
 (“UHN”) 
 -AND- 
 MED
BIOGENE INC., a British Columbia corporation, having a principal office at 300 - 2386 East Mall, Gerald McGavin Building, Vancouver, British Columbia, V6T 1Z3, Facsimile (604) 827-5120 
 (“MBI”; herein UHN and MBI may be referred to individually as a “Party”, or collectively as the
“Parties”.) 
 Whereas: 
  

	A.	Pursuant to an exclusive license agreement (the “Exclusive License Agreement”) between the Parties dated even date herewith and amended as of the
Amendment Date, UHN grants to MBI an exclusive license to further develop and commercialize certain technology developed by UHN researchers Drs. Ming-Sound Tsao and Frances A. Shepherd (collectively, the “Principal Investigators”)
relating to messenger RNA (“mRNA”) expression-based methods for prognosing early-stage non-small-cell lung cancer survival as more specifically described therein (the “Licensed Technology”).

  

	B.	UHN desires to undertake under the direction of the Principal Investigators, and MBI desires to financially support, a research program (the “Research
Program”) relating to prognostic mRNA expression-based signatures to be used in the clinical management of lung cancers, namely the further research, development and validation of the Licensed Technology in respect of said prognostic mRNA
expression-based signatures as more fully outlined in Schedule A attached hereto and in a manner compatible with UHN’s role as a world-class health care research and teaching institution. 

  

	C.	As provided for in the Exclusive License Agreement, UHN grants to MBI an exclusive license to further develop and commercialize the technology developed in the Research
Program. 

  

	D.	MBI and UHN have agreed to enter into an additional sponsored research agreement (the “Additional Sponsored Research Agreement”) and an additional
exclusive license agreement relating to a 15-gene prognostic mRNA expression-based signature to be used in the clinical management of lung cancers, dated effective as of the Amendment Date. 

 NOW THEREFORE THIS AGREEMENT WITNESSES that in consideration for the mutual promises, representations, covenants and agreements of the
Parties contained herein and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties agree as follows. 

 ARTICLE 1 – SCOPE OF WORK 
 1.1 Research Program. UHN, under the direction of the Principal Investigators, will, using commercially reasonable efforts, undertake the Research
Program in accordance with the procedures, specifications and timelines described out in Schedule A attached hereto and this Agreement. The Parties acknowledge that the Research Program will be carried out in vitro utilizing human biological
material and that no in vivo studies will be undertaken. UHN shall ensure that its employees who perform UHN’s obligations under the Research Program are appropriately trained and qualified to perform the obligations in accordance with
the terms of this Agreement. 
 1.2 Principal Investigators. The Research Program will be conducted under the direction of the Principal
Investigators. UHN shall ensure that the Principal Investigators are available to perform the Research Program and shall not replace such persons with any other person without the prior written approval of MBI. In the event of the death, incapacity
or total disability of one or both of the Principal Investigators or one or both of the Principal Investigators ceases employment or terminates his/her association with UHN, UHN shall notify MBI in writing and may nominate one or more replacements.
If no nominee satisfactory to MBI is found, MBI may immediately terminate this Agreement under Section 9.3. 
 1.3 UHN Research Ethics
Board Approval. UHN represents and warrants that it has received, or will receive, all applicable approvals of the UHN Research Ethics Board operating under the Tri-Council Policy Statement, “Ethical Conduct for Research Involving
Humans”, 1998 (the “UHN REB”), as amended from time to time, in respect of undertaking the Research Program and the use of human biological material in respect thereto. 
 1.4 Subcontractors. 
  

	(a)	Any subcontractor used by UHN to perform the Research Program or any other obligations hereunder shall be subject to written obligations that comply with the
requirements set out herein for the performance of the Research Program and provide for the ownership and allocation of Intellectual Property rights and data and the confidentiality of information, record-keeping and access that are consistent with
the intent and terms of this Agreement. UHN shall make copies of each subcontractor agreement available to MBI. 

  

	(b)	UHN shall remain liable for the performance of any of its obligations delegated to a subcontractor. Any breach by UHN’s subcontractors shall be deemed a breach by
UHN, and MBI may proceed directly against UHN for such breach without any obligation to first proceed against such subcontractors. 

 1.5 Delays. UHN shall promptly notify MBI of any factor, occurrence or event that is likely to occasion its delay or failure to perform its obligations under the Research Program in accordance with the timelines therefor. In such
event, the Parties shall cooperate to expedite the performance of the Research Program. 
 ARTICLE 2 - FINANCIAL SUPPORT AND
RESEARCH PROGRAM SUCCESS FEES 
 2.1 Financial Support. Subject to suspension under Section 9.6, MBI shall provide to UHN
financial support to conduct the Research Program in the aggregate amount of $[*] (inclusive of [*]% institutional overhead) (the “MBI Grant”), as more fully outlined in Schedule B attached hereto. MBI shall make such payments in
advance on a quarterly basis commencing on the Effective Date, as set out in the “quarterly payment schedule” detailed in Schedule B, subject to receipt by MBI of any outstanding reports to be provided by the Principal Investigators under
Section 4.2 below. 
 2.2 Application of Funds. UHN hereby agrees that it shall apply the MBI Grant solely in payment of the
Principal Investigators’ costs and expenses in performing the Research Program in accordance with this Agreement. UHN shall apply the funds paid to it in respect of the MBI Grant in accordance with UHN’s internal policies and procedures.

  

	*	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted
portions. 

  

 2 

 2.3 Funds Held in Trust. UHN hereby agrees that all funds paid to it by MBI in respect of MBI Grant
shall be deemed to be held in trust by UHN for the benefit of MBI until applied by UHN to the Principal Investigators’ costs and expenses in accordance with this Article 2. All funds deemed to be held in trust hereunder shall be deemed to be
held separate from and form no part of UHN’s money, assets or revenues, whether or not the amounts so paid have in fact been kept separate and apart from UHN’s money, assets or revenues. 
 2.4 No Other Funding. Without the prior written consent of MBI, UHN and the Principal Investigators agree not to use any funds received from any
Person (as defined below) other than UHN or MBI (a “Third Party”) to support any work specifically performed under the Research Program whereby any rights to the Intellectual Property arising from the Research Program under this
Agreement is or shall be granted to, or is otherwise optioned to, any third party other than MBI. MBI hereby consents to the use of CIHR funding for the Research Program, which the Parties acknowledge will not affect the allocation of ownership
between UHN and MBI of Intellectual Property arising from the Research Program under this Agreement. 
 2.5 Definition of “Successful
Completion”. In this Agreement, “Successful Completion” means material completion by UHN of their work under each relevant Phase of the Research Program within the relevant time period prescribed in Schedule A; provided
that, in respect of each Phase of the Research Program, in the event that there is: 
  

	(a)	a delay in the UHN tumour bank delivering the patient samples for analysis by UHN as outlined in Schedule A, 

  

	(b)	the occurrence of an act of force majeure, as outlined in Section 13.14 below, or an event which is unforeseeable, or 

  

	(c)	any other reasonable delay not contemplated in (a) or (b) above, 

 resulting in UHN not being reasonably able to complete, using reasonable commercial efforts, within the prescribed time period its obligations for Successful Completion thereof, then MBI and UHN shall
promptly and in good faith negotiate an extension to such time period to reflect the delay caused by the act in question to allow UHN a time period to fulfill, using reasonable commercial efforts, its obligations as outlined in Schedule A, including
its obligations for Successful Completion. In particular, Successful Completion means: 
  

	(d)	in respect of Phase 1: 

  

	 	(i)	[*] 

  

	 	(ii)	[*] 

  

	 	(A)	[*] 

  

	 	(B)	[*] 

  

	 	(C)	[*] 

  

	*	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted
portions. 

  

 3 

	 	(D)	[*] 

  

	 	(E)	[*] ; and 

  

	 	(iii)	[*] 

  

	(e)	in respect of each of Phase 2 and Phase 3: 

  

	 	(i)	[*] 

  

	 	(ii)	[*] 

  

	 	(A)	[*] 

  

	 	(B)	[*] 

  

	 	(C)	[*] 

  

	 	(D)	[*] and 

  

	 	(iii)	[*] 

 subject in each case to the completion and
delivery of all data and a detailed report pursuant to Subsection 4.2(b), in form and substance reasonably acceptable to MBI. 
 2.6 Method
of Payment. Payment to be made by MBI hereunder shall be made by certified cheque payable to the order of “University Health Network” and sent to the following address: 
 University Health Network 
 Technology Development & Commercialization 
 College Street - Suite 150 
 Heritage Building - MaRS Centre 
 Toronto, Ontario, Canada, M5G 1L7 
 Attention: Cheryl Adamo - Compliance Specialist

 2.7 Currency. All monetary amounts in this Agreement are in Canadian funds. 
 2.8 Interest. All monies payable to UHN hereunder and not paid when due bear interest at the then prime rate of interest quoted by the Bank of Canada
plus two (2) percentage points per annum until the date paid to UHN. UHN will be entitled to that interest in addition to any other rights or remedies available to it in respect to default in payment by MBI. 
  

	*	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted
portions. 

  

 4 

 ARTICLE 3 - CLINICAL DATA AND PATIENT SAMPLES 
 3.1 Clinical Data. As more fully outlined in Schedule A, UHN shall utilize the Clinical Data (as such term is defined below in Subsection 5.1(a)) to
undertake the analysis under the Research Program and shall collaborate with MBI in analyzing the results of such analysis. Notwithstanding the foregoing, the disclosure to MBI of the raw Clinical Data is in the sole discretion of UHN. Also
notwithstanding the foregoing, UHN shall in good faith deliver to MBI, or directly to the relevant patent or regulatory agencies under assurances of confidentiality, the Clinical Data reasonably required to be disclosed in any Patent or regulatory
filings, including, in respect of the latter, that under the Clinical Laboratory Improvement Amendments regulations and program for the regulation in the United States of laboratory testing administered by the Centers for Medicare &
Medicaid Services (CMS), or the United States Food and Drug Administration regulations, or any successor agencies thereof, or other regulations in the United States or other jurisdictions, in respect of the submission for, or the receipt of,
regulatory approval or clearance of a Licensed Product. 
 3.2 Retention of Samples. Subject to availability, UHN will use reasonable
efforts to retain tissue samples and related materials utilized in the Research Program. The availability of such tissue samples and related materials shall be determined solely by UHN. Notwithstanding the foregoing, UHN and MBI shall negotiate in
good faith terms and conditions (including, without limitation, financial compensation) in respect of the isolation and storage of mRNA samples for transfer to MBI. 
 ARTICLE 4 - COMMUNICATION, RECORDS AND REPORTS 
 4.1 Communication. The Parties are
encouraged to informally communicate with each other during the course of the research activities to keep the other apprised of their activities and of the progress of the Research Program. Sandy Der, Ph.D. shall be the initial UHN contact person in
respect of all such informal communications pertaining to the Research Program. 
 4.2 Records; Reports; Deliverables. UHN and the
Principal Investigators shall keep and maintain complete and accurate written records of the performance of the Research Program, including, without limitation, records of all data, reports, deliverables and inventions. In addition to the informal
communication noted above, UHN will provide to MBI by email the following reports and deliverables: 
  

	(a)	within two (2) weeks after the end of each quarter during the Research Program, a progress report (approximately five pages) summarizing the work completed during
the preceding quarter, including, among other relevant matters, details of the activities undertaken and the accomplishments achieved and challenges faced, progress made in light of the requirements for Successful Completion and the deliverables
outlined in Schedule A in respect of the particular Phase of the Research Program and the development of any Intellectual Property. The Principal Investigators (and their research team, where applicable) and MBI will, as soon as reasonably
practicable after the receipt by MBI of each report, convene a meeting by either by conference or video whereby UHN will present to MBI on the contents of the report and a discussion will ensue; and 

  

	(b)	within two (2) weeks after the completion of each Phase of the Research Program: 

  

	 	(i)	a detailed report (approximately five to seven pages) setting out the results of the research completed during the relevant Phase compared to the deliverables outlined
in the Research Program (and, in particular, evidence of whether or not UHN has achieved Successful Completion described in Section 2.5 above for the Phase), and the development of any Intellectual Property; and 

  

	 	(ii)	copies of all Intellectual Property forming a part of the Licensed Technology arising from the relevant Phase of the Research Program, all in a form and with content
reasonably satisfactory to MBI as required to enable MBI’s reasonably competent staff to further develop and commercialize such technology, including the transfer of such technology to a third party. 

 The results outlined in the report shall be consistent in detail with those found in the publication, in respect of the Licensed Technology,
entitled “Three-gene prognostic classifier for early-stage non-small-cell lung cancer”, Lau, K., et al. (2007), Journal of Clinical Oncology. The Principal

  

 5 

 
Investigators (and their research team, where applicable) and MBI will, as soon as reasonably practicable after the receipt by MBI of each detailed report under this subsection, convene an
in-person meeting at UHN’s facilities whereby UHN will make a presentation to MBI on the contents of the report and a discussion will ensue during which UHN will address technical issues raised by MBI regarding the information so provided.

 4.3 Site Visits. Subject to UHN’s consent in its sole discretion, acting reasonably, MBI’s representatives may, on
reasonable notice, visit UHN’s facilities at reasonable times during normal business hours to observe the performance of the Research Program and discuss the progress and results thereof with the Principal Investigators and their research team,
where applicable. UHN will assist MBI in scheduling such visits. 
 ARTICLE 5 - CONFIDENTIAL INFORMATION 
 5.1 Definitions. In this Agreement: 
  

	(a)	“Clinical Data” means the personal and/or patient-related information and data which may be disclosed by UHN to MBI under this Agreement and/or the
Exclusive License Agreement; 

  

	(b)	“Confidential Information” of a party means any and all information of and disclosed by a Party and/or any of its Affiliates (a “Disclosing
Party”) which has or will come into the possession or knowledge of the other Party and/or any of its Affiliates (a “Receiving Party”) in connection with or as a result of entering into this Agreement and which is marked as
confidential or is identified as confidential at the time of disclosure, including information concerning the Disclosing Party’s past, present and future business, research and development, technology, customers and suppliers. For the purposes
of this definition, “Confidential Information” may include any and all Intellectual Property, Licensed Technology, product, commercial, research, scientific, customer or market information and analyses or conclusions drawn or derived
therefrom; the Disclosing Party’s raw materials, processes, formulations, analytical procedures, methodologies, products, samples, specimens, functions, Know-how, data, patents, copyrights, trade secrets, processes, techniques, programs,
designs, formulae, marketing, advertising, financial, commercial, sales or programming materials, written materials, compositions, drawings, diagrams, computer programs, studies, work in progress, visual demonstrations, ideas, concepts, and other
data, in oral, written, graphic, electronic, or any other form or medium whatsoever. All Clinical Data shall be considered UHN Confidential Information, save and except for such Clinical Data reasonably required to be included in a manuscript for
acceptance of publication made in accordance with Section 5.6. Information shall not be considered “Confidential Information” to the extent that, when considered as a whole and in the context disclosed, the information:

  

	 	(i)	is part of the public domain at the time of disclosure, 

  

	 	(ii)	subsequently becomes part of the public domain through no act or fault of the Receiving Party or its agents or employees, 

  

	 	(iii)	can be demonstrated by the Receiving Party’s written records to have been known or otherwise available to the receiving party prior to the disclosure by the
Disclosing Party, 

  

	 	(iv)	can be demonstrated by the Receiving Party’s written records to have been subsequently provided to the receiving Party, without restriction, by a Third Party who
is not under a duty of confidentiality respecting the information disclosed and who has a legal right to disclose it, 

  

	 	(v)	can be demonstrated by the Receiving Party’s written records was subsequently and independently developed by employees or consultants of the Receiving Party who
had no knowledge of or access to the information disclosed, 

  

	 	(vi)	is required to be disclosed by law or an order of a court, tribunal, or government agency, provided that the Receiving Party gives to the Disclosing Party prompt notice
of the required disclosure in order to allow the Disclosing Party reasonable opportunity to seek a confidentiality order or the like, 

  

 6 

	 	(vii)	is reasonably required to be disclosed by MBI in any Patent filings or under the Clinical Laboratory Improvement Amendments regulations and program for the regulation
in the United States of laboratory testing administered by the Centers for Medicare & Medicaid Services (CMS), or the United States Food and Drug Administration regulations, or any successor agencies thereof, or other regulations in the
United States or other jurisdictions, in respect of the submission for, or the receipt of, regulatory approval or clearance of a Licensed Product, or 

  

	 	(viii)	is identified in writing by the disclosing Party as no longer constituting Confidential Information; and 

  

	(c)	“Person” means and includes any individual, corporation, partnership, firm, joint venture, syndicate, association, trust, government body and any other
form of entity or organization. 

 5.2 Confidentiality. It is contemplated that in the course of the performance of this
Agreement each Party may, from time to time, disclose Confidential Information to the other. Each Party agrees that it shall take all proper measures, and at least the same measures as it takes in respect of its own Confidential Information, to keep
and use in strict confidence all Confidential Information of the other Party and to not, without the prior written consent of the other Party, disclose any such Confidential Information to any Person other than its Affiliates, corporate counsel,
employees, sub-licensees, distributors and contractors who are under an obligation of confidentiality on terms substantially similar to those set out in this Agreement, who have been informed of the confidential nature of the Confidential
Information and as is reasonably required for the development and commercialization of the Licensed Technology under this Agreement. In respect of the Clinical Data, MBI shall comply with all applicable laws, regulations and governmental guidelines
in respect of the protection of personal and/or patient-related information and data. Neither Party will use or disclose to any other Person any of the Confidential Information except as expressly permitted hereunder. 
 5.3 Disclosure to Advisors. Notwithstanding the confidentiality obligations herein, each Party shall be permitted to disclose the terms of this
Agreement and information relating to the Licensed Technology, without the prior written consent of the other Party, to advisors, shareholders, investors, potential investors, underwriters and others on a need to know basis under circumstances that
reasonably ensure the confidentiality thereof, or to the extent required by law. 
 5.4 Ownership of Confidential Information. All
Confidential Information disclosed by one party to the other shall remain the Intellectual Property of the disclosing party. 
 5.5
Publicity; Use of Names. 
  

	(a)	Neither Party shall (i) use the name, trade-mark or trade-name of the other Party in connection with any public statements or disclosures, or the marketing or
advertising of any Licensed Products, or (ii) issue any press release, public announcement or any disclosure in respect of this Agreement and the Exclusive Licence Agreement and any matter associated therewith, without the prior consent of the
other Party, not to be unreasonably withheld. At the request of UHN or MBI respectively, MBI or UHN shall acknowledge the contribution and ownership of UHN and/or MBI to the Licensed Technology, Improvements by UHN PI(s), Improvements by UHN
non-PI(s) or Improvements by MBI, as the case may be. 

  

	(b)	Notwithstanding the foregoing, each Party shall have a right to issue press releases, public announcements or publications, without consent of (but with notice to) the
other Party to the extent that information in any such press release, public announcement or publication has been previously made public or released or to the extent as may be legally required by, for example, the rules and regulations of the
Canadian provincial securities regulators or similar federal, provincial, state or foreign authorities, as determined in good faith by the disclosing Party. 

  

 7 

 5.6 Publication / Principal Investigators as Lead Publishers. Principal Investigators / UHN or MBI
may publish the data and/or results of the Research Program in accordance with normal academic practices but subject to the following conditions: 
  

	(a)	the publishing Party shall grant to the other Party a thirty (30) day period to review any proposed publication of the publishing Party in respect of said Research
Program results; 

  

	(b)	during this review period, the other Party may by notice to the publishing Party: 

  

	 	(i)	require the publishing Party to remove any of the other Party’s Confidential Information, or 

  

	 	(ii)	request a delay in the publication for up to a maximum of an additional sixty (60) days in order to protect the other Party’s proprietary interests;

  

	(c)	for purposes of certainty and clarity, the publishing Party may publish the data and/or results of the work undertaken under the Research Program after the
aforementioned thirty (30) day review period in the absence of any requirement to remove the other Party’s Confidential Information (further to Paragraph (b)(i) above) or after sixty (60) days if the other Party requests a delay of
the publication to protect the other Party’s proprietary interests (further to Paragraph (b)(ii) above); 

  

	(d)	the publishing Party shall recognize in all publications any relevant contributions of UHN and MBI. Subject to Subsection 5.6(e) below, authorship shall be determined
in accordance with the Uniform Requirements for Manuscripts Submitted to Biomedical Journals of the International Committee of Medical Journal Editors (http://www.icmje.org/), or such other practices that are customary for academic
publications, as mutually agreed by the Parties, acting reasonably; 

  

	(e)	the Parties acknowledge that, to facilitate the commercialization of the Licensed Technology, it is essential for the results of the Research Program to be published in
a timely fashion in peer-reviewed journals. Notwithstanding Subsections 5.6(a) to 5.6(d) above, the Parties agree and acknowledge that it is in their best interests, and they fully intend, for the Principal Investigators / UHN to lead, to the extent
that they desire to do so, all publications in respect of the data and/or results of the Research Program. To that extent, MBI shall provide to UHN advance notice of its desire to have published certain data and/or results of the Research Program.
MBI shall not proceed with any proposed publication until the earlier of the Principal Investigators / UHN declining to lead such publication or the expiration of thirty (30) days after the Principal Investigators’ / UHN’s receipt of
such notice from MBI, after which MBI may pursue the proposed publication in accordance with Subsections 5.6(a) to 5.6(d) above and Principal Investigators / UHN shall provide to MBI all reasonable assistance and relevant data and analysis to
facilitate such timely publication. For all publications to be led by the Principal Investigators / UHN , Principal Investigators / UHN shall pursue all such publications in a timely manner in accordance with Subsections 5.6(a) to 5.6(d) above, and
MBI shall provide to UHN all reasonable assistance and relevant data and analysis to facilitate such timely publication. 

 5.7
Duration of Obligation. Unless otherwise agreed by the Parties in writing, the obligations of the Parties relating to Confidential Information set out in this Article 5 shall survive the expiration or termination of this Agreement for a
period of ten (10) years. 
 ARTICLE 6 - INTELLECTUAL PROPERTY 
 6.1 Definitions. In this Agreement: 
  

	(a)	“Improvements by MBI” means any and all improvements to the Licensed Technology made by MBI, its employees and consultants, outside of the Research
Program after the Effective Date, which claim priority to or otherwise rest on claims of the Licensed Patents described in and/or listed in Section 1 of Schedule C, as amended from time to time. 

  

	(b)	 “Improvements by UHN PI(s)” means any and all improvements to the Licensed Technology developed at UHN by the Principal Investigators
(and the UHN personnel, employees, staff members, students, agents and consultants under their direct supervision) outside of the

  

 8 

	 	 
Research Program after the Effective Date, which claim priority to or otherwise rest on claims of the Licensed Patents described in and/or listed in Section 1 of Schedule A, as amended from
time to time; 

  

	(c)	“Improvements by UHN non-PI(s)” means any and all improvements to the Licensed Technology developed at UHN by UHN personnel other than the Principal
Investigators (and the UHN personnel, employees, staff members, students agents and consultants under their direct supervision) outside of the Research Program after the Effective Date, which claim priority to or otherwise rest on claims of the
Licensed Patents described in and/or listed in Section 1 of Schedule A, as amended from time to time; 

  

	(d)	“Intellectual Property” means inventions, discoveries, written material, compounds, patentable and unpatentable information, Know-how, trade secrets,
copyright, designs, plant breeders’ rights, integrated circuit topographies, ideas (including but not limited to any computer software), formulae, algorithms, concepts, proprietary data, techniques, instructions, processes, expert opinions,
information, materials, program listings, flow charts, logic diagrams, manuals, specifications, instructions, or any copies of the foregoing in any medium, or the expression thereof; 

  

	(e)	“Intellectual Property Rights” means any proprietary, possessory, use and ownership rights, titles and interests (whether beneficial or legal) of all
kinds whatsoever, in and to any Intellectual Property, including by way of Patents, Patent applications, trade-marks, trademark applications, copyrights, copyright applications, industrial designs, industrial design applications, Know-how and trade
secrets, and all other intellectual and industrial property rights whatsoever and world-wide (whether registered or unregistered and including rights in any application for any of the foregoing); 

  

	(f)	“Joint Research Program IP” means any and all Intellectual Property conceived or developed with contributions by both UHN and MBI (which includes their
respective personnel, staff members, employees, students, agents and consultants) pursuant to activities conducted in respect of the Research Program under the Sponsored Research Agreement, including, without limitation, the Licensed Patents
described in and/or listed in Section 3 of Schedule C, as amended from time to time; 

  

	(g)	“Know-how” means any information pertaining to a technology which is not disclosed in a patent or published patent application, and includes
trade-secrets; 

  

	(h)	“Licensed Patents” means the Patents described in and/or listed in Schedule A, as amended from time to time; 

  

	(i)	“Licensed Technology” means: 

  

	 	(i)	the UHN Existing IP, 

  

	 	(ii)	the UHN Research Program IP, and 

  

	 	(iii)	the Joint Research Program IP, 

 but excluding any Improvements by UHN PI(s) and any Improvements by UHN non-PI(s) and UHN Other IP, unless expressly agreed in writing by the Parties to be included hereunder pursuant to the Exclusive License Agreement; 
  

	(j)	“MBI Research Program IP” means any and all Intellectual Property conceived or developed solely by MBI (which includes its personnel, staff members,
employees, students, agents and consultants) pursuant to activities conducted specifically in respect of the Research Program under this Agreement; 

  

	(k)	“Patent” shall mean: 

  

	 	(i)	any issued patent or patent application, 

  

	 	(ii)	all continuations and continuations-in-part applications to the issued patent or patent application set out in Paragraph (i) (solely to the extent such
continuations-in-part applications contain subject matter on which claims issuing obtain the benefit of a priority date of any patent or patent application set out in Paragraph (i)), 

  

 9 

	 	(iii)	all divisions, patents of addition, reissues, renewals and extensions of any of the patent, patent application, continuations and continuations-in-part applications set
out in Paragraphs (i) and (ii), and 

  

	 	(iv)	all foreign counterparts of any of the foregoing (including, without limitation, European Supplementary Protection Certificates or its equivalent);

  

	(l)	“UHN Existing IP” means UHN’s pre-existing background Intellectual Property relevant to the Research Program, including, without limitation, the
Licensed Patents described in and/or listed in Section 1 of Schedule C, as amended from time to time, and the relevant Clinical Data; and 

  

	(m)	“UHN Research Program IP” means any and all Intellectual Property conceived or developed solely by UHN (which includes its personnel, staff members,
employees, students, agents and consultants) pursuant to activities conducted specifically in respect of the Research Program under this Agreement, including, without limitation, the Licensed Patents described in and/or listed in Section 2 of
Schedule C, as amended from time to time. 

 6.2 Background Intellectual Property. Each Party’s pre-existing
background Intellectual Property relevant to the Research Program (comprising UHN Existing IP and MBI Existing IP) and any other Intellectual Property developed independently of, or arising from activities not solely and specifically conducted
pursuant to the conduct of, the Research Program by a Party (the latter hereinafter referred to as “UHN Other IP” and “MBI Other IP” respectively), shall be owned by that Party. For purposes of certainty and
clarity, 
  

	(a)	UHN Other IP shall include, but not be limited to, all Intellectual Property generated or otherwise created by UHN and/or Principal Investigator(s) related to:

  

	 	(i)	prognostic and/or diagnostic genetic-based approaches and/or methodologies of general application, 

  

	 	(ii)	prognostic and/or diagnostic DNA-based approaches and/or methodologies for any application, and 

  

	 	(iii)	prognostic and/or diagnostic protein-based approaches and/or methodologies for any application, 

 and UHN Other IP shall exclude prognostic mRNA expression-based signatures for the clinical management of lung cancers; and 
  

	(b)	UHN Research Program IP, MBI Research Program IP and Joint Research Program IP shall not include or otherwise encompass UHN Other IP. Other than as set out in this
Agreement and the Exclusive License Agreement, no Party shall obtain any rights in another Party’s background Intellectual Property or Other IP. 

 6.3 Research Program Intellectual Property. Subject to Section 6.2: 
  

	(a)	UHN shall solely own all right, title and interest in and to all UHN Research Program IP; 

  

	(b)	MBI shall solely own all right, title and interest in and to all MBI Research Program IP; and 

  

	(c)	UHN and MBI shall jointly own all right, title and interest in and to Joint Research Program IP. 

 6.4 Disclosure of Inventions. 
  

	(a)	 Each Party shall disclose to the other Party any patentable Intellectual Property conceived and reduced to practice in the conduct of the Research
Program that may form the subject matter of a Patent (each, an “Invention”), as set out herein. In respect of UHN, a Principal Investigator shall disclose to UHN in writing, in accordance with UHN’s intellectual property
policy, any potential Invention made by UHN. UHN shall formally disclose the Invention to MBI by written notice in

  

 10 

	 	 
accordance with UHN’s intellectual property policy. In respect of MBI, MBI shall provide written notification to UHN of any potential Invention made by MBI via an analogous written notice
(hereinafter, said written notices referred to as an “Invention Notice”). 

  

	(b)	Within sixty (60) days after a Party receives an Invention Notice from the other Party, the Parties shall meet to discuss whether to pursue Patent protection and,
if and/or as appropriate, their respective roles and responsibilities (including financial) in respect of this pursuit of Patent protection. Subject to the terms of the Exclusive License Agreement, and absent any additional agreement(s) between the
Parties: 

  

	 	(i)	each Party shall have sole responsibility for the prosecution and/or maintenance of any application and/or registration for any Intellectual Property Rights solely
owned by it; and 

  

	 	(ii)	the Parties shall have joint responsibility for the prosecution and/or maintenance of any application and/or registration for Intellectual Property Rights jointly owned
by the Parties. 

 6.5 Research Licenses. The Parties shall, and do hereby grant to each other all required licenses (on a
non-exclusive, non-sublicenseable, royalty-free, for research and development purposes only basis) in respect of an individual Party’s Intellectual Property necessary for the other Party to conduct the activities contemplated hereunder this
Agreement. 
 6.6 Commercialization Licenses. The granting of licenses by one Party to the other in regards to the commercialization of
Intellectual Property arising from the activities conducted pursuant to this Agreement and in respect of a Party’s background Intellectual Property shall be governed by the terms and provisions of the Exclusive License Agreement. 
 6.7 Avoidance of Third Party Rights. Subject to Section 6.10, neither UHN nor the Principal Investigators shall knowingly engage in any
activities, on their own or in collaboration with a third party, or use any third party facilities or third party Intellectual Property in performing the Research Program which could result in any claims of any ownership interest in any inventions
being made by such third party, without MBI’s prior written consent. 
 6.8 Intellectual Property Representations and Warrantees.
The Parties acknowledge that neither Party makes any representation or warranty with respect of the following: 
  

	(a)	whether any third party may have any right or interest in any Intellectual Property arising out the Research Program; 

  

	(b)	whether any Invention will be covered by any Patent or Patent application or any other form of Intellectual Property registration. 

 The Parties further acknowledge that it may be necessary to reach agreements with Third Parties in order to permit the use and exploitation of the results
of the Research Program and of any Intellectual Property arising therefrom. To the best of the knowledge of UHN as on the Effective Date, neither UHN nor the Principal Investigators are aware of any Intellectual Property Rights of any Third Party in
or to any Intellectual Property relating to the Licensed Technology. 
 6.9 Infringement. The Parties acknowledge and agree that the
terms of the Exclusive License Agreement shall govern the prosecution and defense of any actions relating to any alleged infringement of the Licensed Technology by third parties or any alleged infringement of third party Intellectual Property by the
Licensed Technology. 
 6.10 Other Research. MBI acknowledges that: 
  

	(a)	UHN (for purposes of this Section 6.10, namely personnel, staff and employees other than the Principal Investigators); and 

  

	(b)	the Principal Investigators; 

  

 11 

 have received and/or shall continue to receive, funding from other sources (in addition to the Canadian
Institutes of Health Research (“CIHR”) funding to be applied to the Research Program) to conduct similar and/or related research to that contemplated by the Research Program. MBI acknowledges that it shall not have any claim to the
work product of the other sources of funding (other than CIHR funding within the Research Program) in law or otherwise, other than the option described in Section 6.11 below or as may be separately negotiated and agreed to by the Parties.

 6.11 Option for Independent Inventions. 
  

	(a)	UHN hereby grants to MBI a right of first negotiation for an exclusive, royalty-bearing license, with the right to grant sublicenses without consent, for the
commercialization of any Intellectual Property pertaining to prognostic mRNA expression-based tests for use in the clinical management of lung cancers, developed by UHN during the term of this Agreement independently of the Licensed Technology and
the Research Program (each, an “Independent Invention”), exercisable in accordance with Subsection 6.11(b), provided that such right of first negotiation and any resulting license will be subject to Section 6.12.

  

	(b)	UHN will provide MBI with written notice disclosing each Independent Invention promptly after UHN files a Patent application for such Independent Invention, which
notice shall be accompanied by sufficient data and other information to enable MBI to evaluate such Independent Invention (a “Notice of Independent Invention”). MBI will have a period of six (6) months after receiving each
Notice of Independent Invention from UHN to provide written notice to UHN of its intent to license the disclosed Independent Invention (“Notice of Intent”). If UHN does not receive a Notice of Intent within such six (6) month
period, MBI’s right of first refusal will lapse and UHN shall be free to license or otherwise exploit the Independent Invention in its sole discretion without any further notice to MBI, and MBI shall have no further claim on, or to, the
Independent Invention. After a Notice of Intent has been received, both Parties shall diligently and in good faith negotiate the addition of such Independent Invention to the Exclusive License Agreement or the licensing thereof under a separate
license agreement. Any such separate license shall be on terms and conditions that are consistent with other such licenses within the industry and satisfactory to UHN. If the Parties have not agreed on the license agreement within nine
(9) months of receipt of a Notice of Intent, UHN shall be free to license or otherwise exploit the Independent Invention in its sole discretion, on terms not more favourable to the licensee than the most favourable terms offered to MBI, without
any further notice to MBI, and MBI shall have no further claim on, or to, the Independent Invention. 

  

	(c)	This Section 6.11 shall survive the expiration or earlier termination of this Agreement for a period of one (1) year. 

 6.12 Third Party Rights. Each right of first negotiation and each license granted to MBI by UHN in and to any Independent Inventions under
Section 6.11 will be subject to the following Third Party Intellectual Property Rights: 
  

	(a)	for any Independent Invention developed by one or both Principal Investigators or those UHN employees, personnel, staff and students under their direct supervision:

  

	 	(i)	any Third Party Intellectual Property Rights existing on or before October 19, 2007 (the “Reference Date”), and 

  

	 	(ii)	any Third Party Intellectual Property Rights arising after the Reference Date pursuant to a research program initiated and funded from inception by a Third Party
pursuant to a written research agreement; and 

  

	(b)	for any Independent Invention developed by any UHN employees, personnel, staff or students, other than those noted in Subsection 6.12(a), any Third Party Intellectual
Property Rights. 

 For each Independent Invention for which MBI has a right of first negotiation, UHN and MBI shall cooperate and
work together, prior to any Third Party being granted any interest in the Intellectual Property Rights in such Independent Invention, to review the merits of any claims made by any Third Parties to the Intellectual Property Rights in such
Independent Invention. For each Independent Invention

  

 12 

 
for which MBI has delivered a Notice of Intent, and for which no Third Party claim is substantiated, UHN and MBI shall in good faith negotiate a license to MBI for the Intellectual Property
Rights in the Independent Invention. UHN shall keep MBI apprised of any facts that may arise from time to time where a Third Party may have or make a claim to Intellectual Property Rights in any Independent Invention. If a Third Party makes an
unsubstantiated claim to Intellectual Property Rights in an Independent Invention, UHN and MBI shall cooperate on the appropriate course of action to defend against any such claim or challenge, restrain or enjoin any Intellectual Property Rights
asserted by the Third Party in UHN’s discretion, acting reasonably, and in good faith in order to protect MBI’s interests in such Intellectual Property Rights. UHN shall take the lead in discussions with any Third Parties relating to any
such claims; provided that, in the unlikely event of litigation, MBI shall have the right to control any such litigation, including the right to settle any dispute in any manner it deems expedient, and UHN shall reasonably assist MBI in connection
therewith. 
 6.13 Current Research of Principal Investigators. UHN represents and warrants that, as of the Reference Date and continuing
to the Effective Date, the Principal Investigators and those UHN employees, personnel, staff and students under their direct supervision have not developed, and/or are not developing (other than in respect of the Licensed Technology and the
technology being developed under the Research Program) any technology or Intellectual Property similar to the Licensed Technology specifically encompassing prognostic mRNA expression-based signatures to be used in the clinical management of lung
cancers, other than that listed in Schedule D attached hereto (which information MBI shall keep strictly confidential as per the confidentiality provisions outlined in Article 5 hereto). 
 6.14 Current Research of Other UHN Researchers. UHN represents and warrants that, to the best of UHN’s knowledge as on the Effective Date, no UHN staff member, researcher or employee
(excluding the Principal Investigators and those UHN employees, personnel, staff and students under their direct supervision) has developed, and/or are developing, as of the Reference Date and continuing to the Effective Date, any technology or
Intellectual Property similar to the Licensed Technology specifically encompassing prognostic mRNA expression-based signatures to be used in the clinical management of lung cancers. 
 ARTICLE 7 - INDEMNIFICATION 
 7.1 Mutual Indemnity. Subject to
Article 8 below, each Party agrees to be responsible and to assume liability for its acts or omissions, and those of its officers, agents, personnel, employees, staff or students, arising out of or as a result of, or in connection with the conduct
of the Research Program, to the full extent required by law. A Party that is negligent or that breaches this Agreement agrees to indemnify, defend and hold the other Party harmless from liability resulting from its negligence or breach, including,
without limitation, legal fees and costs, except to the extent caused by the other Party, and each Party agrees to maintain reasonable insurance coverage for such liabilities. 
 ARTICLE 8 - REPRESENTATIONS, WARRANTEES & LIABILITY 
 8.1
General Representations. Each Party represents and warrants to the other Party that it 
  

	(a)	is duly incorporated and organized and validly existing under the laws of its jurisdiction of incorporation and has all requisite corporate power and authority to enter
into and perform its obligations under this Agreement; and 

  

	(b)	has taken all necessary corporate action, steps and proceedings to approve or authorize, validly and effectively, the execution and delivery of this Agreement and the
performance of its obligations hereunder. 

 8.2 NO WARRANTIES. EXCEPT AS EXPRESSLY PROVIDED IN THIS AGREEMENT, NEITHER
PARTY, NOR THE PRINCIPAL INVESTIGATORS, MAKES ANY WARRANTIES, REPRESENTATIONS OR GUARANTEES OF ANY KIND WHATSOEVER, EITHER EXPRESS OR IMPLIED, REGARDING

  

 13 

 
THE RESEARCH PROGRAM AND ANY INTELLECTUAL PROPERTY, INVENTIONS OR PRODUCTS ARISING THEREFROM TO BE SUPPLIED UNDER THIS AGREEMENT, INCLUDING, BUT NOT LIMITED TO, ANY WARRANTY OF ORIGINALITY OR
ACCURACY OR ANY EXPRESS OR IMPLIED WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. MBI ACKNOWLEDGES THAT IT ASSUMES THE ENTIRE RISK FOR THE DESIGN, DEVELOPMENT, MANUFACTURE, SALE OR OTHER DISPOSITION AND PERFORMANCE OF PRODUCTS
INCORPORATING INTELLECTUAL PROPERTY ARISING FROM THE RESEARCH PROGRAM. 
 8.3 NO CONSEQUENTIAL DAMAGES. EXCEPT AS OTHERWISE EXPRESSLY
PROVIDED IN THIS AGREEMENT, IN NO EVENT SHALL EITHER PARTY, NOR THE PRINCIPAL INVESTIGATORS, BE LIABLE FOR ANY SPECIAL, INDIRECT, CONSEQUENTIAL, OR INCIDENTAL DAMAGES OR LOST PROFITS, HOWEVER CAUSED, ON ANY THEORY OF LIABILITY, SUFFERED BY THE OTHER
PARTY OR ANY THIRD PARTY RESULTING FROM THE USE OF THE RESULTS OF THE RESEARCH PROGRAM, OR ANY INTELLECTUAL PROPERTY, INVENTIONS, PRODUCTS OR PATENTS ARISING THEREFROM. 
 ARTICLE 9 - TERM AND TERMINATION 
 9.1 Term. This Agreement shall commence on the
Effective Date and continue for a period of two (2) years thereafter unless extended or earlier terminated as set out below. Each extension or renewal of this Agreement shall require the prior written approval of the Parties. 
 9.2 Termination by UHN. UHN may terminate this Agreement on written notice to MBI: 
  

	(a)	if prior to the completion of Phase I of the Research Program, MBI fails to meet any of its material obligations under this Agreement and does not remedy these failures
within thirty (30) days after receipt of notice of such failure from UHN; 

  

	(b)	if subsequent to the completion of Phase I of the Research Program, MBI fails to meet any of its material obligations under this Agreement and does not remedy these
failures within ninety (90) days after receipt of notice of such failure from UHN; or 

  

	(c)	immediately upon UHN giving notice to MBI at any time: 

  

	 	(i)	MBI files a voluntary petition in bankruptcy or insolvency or shall petition for reorganization under any bankruptcy law, or makes a general assignment for the benefit
of creditors, or otherwise acknowledges insolvency or is adjudged bankrupt, 

  

	 	(ii)	MBI shall consent to an involuntary petition in bankruptcy or if a receiving order is given against it under the Bankruptcy and Insolvency Act (or such other equivalent
Act in the respective jurisdiction), or 

  

	 	(iii)	the appointment of a receiver or other similar representative for MBI by a court of competent jurisdiction. 

 9.3 Termination by MBI. MBI may terminate this Agreement on written notice to UHN: 
  

	(a)	immediately in the event that one or more Principal Investigators unable to continue the direction of the Research Program as described under Section 1.2, and no
replacement satisfactory to MBI has been found; 

  

	(b)	immediately at any time after UHN fails to achieve Successful Completion of any Phase of the Research Program within the timelines set out in Schedule A or such other
timelines as may be agreed to by the Parties; 

  

	(c)	immediately at any time after achievement of Successful Completion of any Phase of the Research Program, if MBI determines, in good faith and utilizing sound and
reasonable business practice and judgment, that in light of the results of the Research Program the further development and commercialization of the Licensed Technology under the Research Program is not advisable; 

  

 14 

	(d)	immediately in accordance with Section 9.6; or 

  

	(e)	if UHN fails to meet any of its other material obligations under this Agreement and does not remedy these failures within thirty (30) days after receipt of notice
of such failure from MBI. 

 9.4 Payment of Outstanding Expenses Upon Termination. Upon termination of this Agreement, the
funds provided by MBI under the MBI Grant shall be applied only to expenses outlined in Schedule B incurred by the Principal Investigators as of the date of notice of termination provided by MBI or UHN, as the case may be. Any amounts held by UHN on
account of the MBI Grant which are in excess of the expenses incurred shall be promptly repaid to MBI. 
 9.5 Effect of Termination. In
the event of the expiration or early termination of this Agreement: 
  

	(a)	upon receipt of notice of termination, UHN shall immediately cease all further work with respect to the Research Program; 

  

	(b)	all of UHN’s rights to use the Confidential Information of MBI shall terminate and UHN shall return to MBI all parts of the Confidential Information of MBI and any
copies thereof in the possession or control of UHN, the Principal Investigators or their research team; 

  

	(c)	if the Exclusive License Agreement is terminated, all of MBI’s rights to use the Confidential Information of UHN shall terminate and MBI shall return to UHN all
parts of the Confidential Information of UHN and any copies thereof in the possession or control of MBI; 

  

	(d)	if the Exclusive License Agreement survives the termination of this Agreement: 

  

	 	(i)	MBI’s use of UHN’s Confidential Information will continue to be governed by the confidentiality provisions of the Exclusive License Agreement; and

  

	 	(ii)	UHN shall provide to MBI copies of all Intellectual Property forming a part of the Licensed Technology arising from the Research Program, whether or not complete, all
in a form and with content reasonably satisfactory to MBI as required to enable MBI’s reasonably competent staff to further develop and commercialize such technology and/or transfer such technology to a third party for further research and
development. UHN shall also conduct a technical review meeting with MBI to address issues raised by MBI regarding the information so provided. 

 9.6 Suspension of Research Program by MBI. 
  

	(a)	After the completion of Phase I of the Research Program, and the payment of the Phase I Research Program success fee in the event of Successful Completion thereof
pursuant to the Exclusive License Agreement, MBI may by written notice to UHN: 

  

	 	(i)	suspend the work under this Agreement, including all research work and financial support under the Research Program; or 

  

	 	(ii)	immediately terminate this Agreement; 

 to focus research under the Additional Sponsored Research Agreement; provided that if the work under the Additional Sponsored Research Agreement is suspended or MBI has terminated the Additional Sponsored Research Agreement in order to
focus research under this Agreement, MBI may not suspend or terminate this Agreement pursuant to this Section 9.6. For greater certainly, UHN shall be eligible under the Exclusive License Agreement for payment of the Phase I Research Program
success fee in respect of Successful Completion thereof, notwithstanding any subsequent suspension of the work under this Agreement or the termination of this Agreement. 
  

	(b)	At any time while the work under this Agreement is suspended, MBI may by written notice to UHN: 

  

	 	(i)	immediately terminate this Agreement; or 

  

 15 

	 	(ii)	resume the work under this Agreement, provided that MBI reimburses UHN for the direct costs incurred by UHN (and not already reimbursed by MBI) in continuing the
Research Program while the work was suspended by MBI. 

  

	(c)	In the event MBI resumes the work under this Agreement, MBI and UHN shall, in good faith, discuss and mutually agree upon: 

  

	 	(i)	the scope of the work undertaken, and direct costs incurred, by UHN in continuing the Research Program while the work was suspended by MBI; 

  

	 	(ii)	any appropriate Research Program success fees payable to UHN under the Exclusive License Agreement in light of the work undertaken by UHN in continuing the Research
Program while the work was suspended by MBI; 

  

	 	(iii)	the work to be undertaken by UHN to complete the remaining portions of the Research Program; and 

  

	 	(iv)	any amendments to the Budget and to the applicable Research Program success fees under the Exclusive License Agreement to complete the remaining portions of the
Research Program. 

 9.7 Survival. The Parties agree the provisions of Subsection 1.4(b), Sections 2.8, 6.1 through 6.4,
6.6, 6.8 through 6.10, 9.5 and 9.7, and Article 3, Article 5, Article 7, Article 8, Article 10, Article 11, Article 12 and Article 13 shall remain in full force and effect after the expiration or earlier termination of this Agreement, until such
time as the Parties mutually agree to the release of the obligations contained therein. The Parties agree the provisions of Section 6.11 shall remain in full force and effect after the expiration or earlier termination of this Agreement in
accordance with the period set out therein. 
 ARTICLE 10 - NOTICES 
 10.1 Notices. All notices which are required or permitted to be given hereunder including judicial payment notices must be in writing. All such
notices must be sent as follows: 
  

			
	If to UHN:	  	 University Health Network
 College Street - Suite 150
 Heritage Building - MaRS Centre
 Toronto, Ontario M5G 1L7, Canada
 Telephone: (416) 581-7410
 Facsimile: (416) 977-4765
  
 Attention: Brian H. Barber, PhD,
                  Director, Technology
                  Development & Commercialization

		
	With a copy to the Principal Investigators:	  	 Ming-Sound Tsao, MD
 Princess Margaret Hospital
 7th Floor, Room 7-613
 University Avenue
 Toronto, Ontario
 Canada M5G 2M9
 Telephone: (416) 340-4737
 Facsimile: (416) 340-5517

  

 16 

			
		
		  	 Frances A. Shepherd, MD
 Princess Margaret Hospital
 5th Floor, Room 5-104
 University Avenue
 Toronto, Ontario
 Canada M5G 2M9
 Telephone: (416) 946-4522
 Facsimile: (416) 946-6546

		
	If to MBI:	  	 Med BioGene Inc.
 #300
– 2386 East Mall
 Gerald McGavin Building
 Vancouver, British Columbia
 Canada V6T 1Z3
 Telephone: (604) 827-5100
 Facsimile: (604) 827-5120
  
 Attention: Erinn B. Broshko,
                  Chief Executive Officer

 or to such other address as the recipient may have designated by notice given in accordance with this Article 10. Any such notice may be delivered by hand,
by registered mail, or sent by facsimile and will be deemed to have been delivered on the date of delivery if delivered by hand, five (5) days after mailing if sent by registered mail, or on the first business day following the date of sending,
if sent by facsimile. 
 ARTICLE 11 - DISPUTE RESOLUTION 
 11.1 Dispute Resolution. In the event of any dispute, controversy or claim among the Parties arising out of or in connection with this Agreement, or the breach thereof, or in respect of any defined
legal relationship associated therewith or derived therefrom, the Parties agree to resolve the dispute in accordance with the following procedures outlined in this Article 11, subject to Subsection 11.5(d). 
 11.2 Good Faith Negotiations. A Party may notify the other Party in writing that a dispute has arisen. The Parties will, in the first instance,
attempt to resolve the dispute, controversy, claim or allegation of breach by entering into good faith negotiations. The Parties shall meet to attempt, in good faith, to resolve the dispute by negotiation, either directly or through the assistance
of such advisors as they may engage. If, within seven (7) days, the Parties do not reach agreement on the resolution of the dispute, the Parties agree to proceed to mediation as set out in Section 11.3 below. 
 11.3 Mediation. Subject to Section 11.2, the Parties shall mediate their dispute before a mediator who is a member of Ontario’s Mandatory
Mediation Program Roster of mediators having appropriate experience in the biopharmaceutical industry. If the Parties fail to agree on a mediator within fourteen (14) days after the decision to proceed to mediation, either Party may apply to a
court of competent jurisdiction to appoint an qualified mediator having appropriate experience in the biopharmaceutical industry. Mediation shall be carried out by the mediator within twenty-one (21) days of the mediator’s appointment.

 11.4 Arbitration. 
  

	(a)	Subject to Sections 11.2 and 11.3, if the Parties fail to resolve their dispute within seven (7) days of the start of the mediation, the Parties will appoint
an arbitrator having appropriate experience in the biopharmaceutical industry who will conduct an arbitration of the dispute. If the Parties cannot agree on a mutually acceptable arbitrator within seven (7) days of the decision to proceed to
arbitration, either Party may apply to a court of competent jurisdiction to appoint an qualified arbitrator having appropriate experience in the biopharmaceutical industry. The arbitration shall be conducted in accordance with the Arbitration
Act, 1991 (Ontario) and the arbitrator shall also be empowered to hear injunctive proceedings in accordance therewith. 

  

 17 

	(b)	Notwithstanding Section 11.5 below, the arbitrator may include in its award an order as to the payment of the costs of the proceedings and reasonable counsel fees.
Any Party ordered to pay costs may avail itself of any procedure for the taxing of costs, provided, however, that the Parties specifically agreed that the officer taxing such costs need not be bound by any statutory scale of costs.

  

	(c)	The arbitrator will make its decision in writing within fifteen (15) days of the hearing and, unless the Parties otherwise agree, the arbitrator’s reasons
will be set out in the award. The award shall be final and binding on the Parties and shall not be subject to any appeal although either Party may request clarification of the award and the arbitrator’s reasons. 

  

	(d)	The Parties consent to the award of the arbitrator being entered in any court having jurisdiction for the purposes of enforcement. In addition, if it appears to any
Party that the arbitrator lacks the power to give effective interim relief, such Party may apply to any appropriate court for such relief. 

  

	(e)	All matters in dispute, all claims, submissions, evidence and findings, and the award itself shall be kept confidential by the arbitrator, and no information regarding
any of the foregoing will be released to any Third Party or otherwise made public without the written consent of the Parties, except as otherwise contemplated herein and except for such information which is not Confidential Information.

  

	(f)	The Parties may with mutual consent, expand or abridge the time periods provided for in this Article 11. 

 11.5 General. 
  

	(a)	The expenses of the mediation or arbitration shall be borne equally by the Parties. Notwithstanding the foregoing, the mediator or arbitrator may include in his or her
award an order as to the payment of the costs of the proceedings and reasonable counsel or other advisor fees. Any Party ordered to pay costs may avail itself of any procedure for the taxing of costs; provided, however, that the Parties specifically
agree that the officer taxing such costs need not be bound by any statutory scale of costs. 

  

	(b)	All meetings and hearings will be in private unless the Parties otherwise agree. 

  

	(c)	Any Party may be represented at any meetings or hearings by legal counsel or any other advisor. 

  

	(d)	Notwithstanding this Article 11: 

  

	 	(i)	disputes relating to the sufficiency of grounds for termination under Sections 9.2 or 9.3 shall not be subject to this Article 11; and 

  

	 	(ii)	either party shall be free to submit any dispute relating to Intellectual Property to any court having jurisdiction over the Parties and the subject matter of the
dispute and to seek such relief and remedies as are available in that court. 

 ARTICLE 12 - COMPLIANCE WITH
LAWS AND REGULATIONS 
 12.1 Compliance with Laws. The Parties shall comply, and agree that the provisions of this Agreement are
intended to be interpreted and implemented so as to comply, with all applicable laws, governmental rules and regulations; however, if it is determined that any provision of this Agreement is not in such compliance, or if the UHN Research Ethics
Board or other comparable body objects to the terms of this Agreement or the provision or use of human biological material hereunder, then the Parties agree to modify that provision, or this Agreement so as to be in compliance with, or to be
acceptable to, such body. 
  

 18 

 ARTICLE 13 - GENERAL TERMS AND CONDITIONS 
 13.1 Entire Agreement. The Parties hereto acknowledge that this Agreement and its schedules, together with the Exclusive License Agreement, set forth
the entire agreement and understanding of the Parties hereto as to the subject matter hereof, and supersedes all prior discussions, agreements and writings in respect hereto. 
 13.2 Schedules. The following schedules are annexed to and form part of this Agreement: 
 Schedule A – Research Program 
 Schedule B – Budget 
 Schedule C – Licensed Patents 
 Schedule D – Section 6.13 Disclosure 
 13.3 General Assurances. The Parties
hereto agree to do all such reasonable things and to execute such instruments and documents as may be reasonably necessary or desirable in order to carry out the provisions and intent of this Agreement. 
 13.4 Enure to Benefit. This Agreement shall enure to the benefit of and be binding upon the respective Parties hereto and, where the context admits
or requires, their respective permitted successors or assigns. 
 13.5 Assignment. This Agreement cannot be assigned, sold, transferred
or encumbered in any manner by a Party without the expressed written consent of the other Party, which consent will not be unreasonably withheld. 
 13.6 No Joint Venture. Each Party is and will remain at all times independent of each other. The Parties are not and shall not be considered to be joint venturers, partners or agents of each other and neither of them shall have the
power to bind or obligate the other except as set forth in this Agreement. The Parties mutually covenant and agree that neither shall they, in any way, incur any contractual or other obligation in the name of the other, nor shall they have liability
for any debts incurred by the other. No representation will be made or acts taken by any of the Parties which could establish any apparent relationship of agency, joint venture, partnership or employment. 
 13.7 Waiver. No amendment, supplement or waiver of any provision of this Agreement shall be binding on any Party unless consented to in writing by
such Party. No waiver of any provision of this Agreement shall constitute a waiver of any other provision, nor shall any waiver constitute a continuing waiver unless otherwise expressly provided. Further, no failure or delay by any Party in
exercising any right or remedy shall operate as a waiver thereof, nor shall any single or partial exercise or waiver of any right or remedy preclude its further exercise or the exercise of any other right or remedy. 
 13.8 Time of the Essence. Time is of the essence in this Agreement and of each and every term and condition hereof. 
 13.9 Headings. The headings in this Agreement are for convenience of reference only and shall not affect the interpretation of this Agreement. Any
reference in this Agreement to an article, section, sub-section or Schedule refers to the specified article, section, sub-section or schedule to this Agreement. 
 13.10 Number, Gender and Persons. In this Agreement, words importing the singular number shall include the plural and vice versa, words importing gender shall include all genders and words
importing persons shall include individuals, corporations, partnerships, associations, trusts, unincorporated organizations, governmental bodies and other legal or business entities. 
 13.11 Joint Preparation. This Agreement shall be deemed to be jointly prepared by the Parties, and any ambiguity herein shall not be construed for or against any Party. 
  

 19 

 13.12 Governing Law. This Agreement shall be governed by the laws of the Province of Ontario and the
laws of Canada applicable therein, and shall be treated as an Ontario contract. The Parties irrevocably and unconditionally submit to the non-exclusive jurisdiction of the courts of the Province of Ontario and all courts competent to hear appeals
therefrom in connection with any matters arising under this Agreement. 
 13.13 Severability of Provisions. In the event that any
provisions of this Agreement are determined to be invalid or unenforceable by a court of competent jurisdiction in any jurisdiction, the remainder of the Agreement shall remain in full force and effect without said provision in said jurisdiction and
such determination shall not affect the validity or enforceability of such provision or the Agreement in any other jurisdiction. The Parties shall in good faith negotiate a substitute clause for any provision declared invalid or unenforceable, which
shall most nearly approximate the intent of the Parties in entering this Agreement. 
 13.14 Force Majeure. In the event that any one of
the Parties is prevented from fulfilling any of its obligations herein by acts of God, war, strikes, riots, storms, fires, governmental orders or restrictions or any other cause beyond its control, the payment of owed monies, or the applicable pro
rata portion thereof, shall be suspended during the full period of any such prevention, but payment of monies which has accrued for payment prior to, or after such cause shall not be excused. 
 13.15 Accounting Principles. Any reference in this Agreement to generally accepted accounting principles refers to generally accepted accounting
principles as approved from time to time by the Canadian Institute of Chartered Accountants or any successor institute. 
 13.16 Best of
Knowledge. “To the best of the knowledge” or “to the knowledge”, unless otherwise qualified hereunder means a statement of the declaring party’s knowledge of the actual facts or circumstances to which such phrase relates
without having made any inquiries or investigations in connection with such facts and circumstances. 
 13.17 Counterparts and Facsimile.
This Agreement may be executed in counterparts and by facsimile each of which shall be deemed an original but all of which together shall constitute one and the same instrument. 
 IN WITNESS WHEREOF, MBI and UHN have executed this Agreement through their duly authorized representatives as of the Effective Date. 
  

									
	MED BIOGENE INC.	 		 	UNIVERSITY HEALTH NETWORK
					
	by:	 	/s/ ERINN B. BROSHKO	 		 	by:	 	/s/ CHRISTOPHER J. PAIGE
		 	Erinn B. Broshko	 		 		 	Christopher J. Paige, Ph.D.
		 	Chief Executive Officer	 		 		 	Vice President, Research

 We, the Principal Investigators,
have read the provisions of this Agreement and will use our best efforts as employees and/or staff members of UHN to direct the Research Program in accordance with said provisions and as directed by UHN. 
  

					
	Principal Investigators	 		 	
			
	/s/ MING-SOUND TSAO	 		 	/s/ FRANCES A. SHEPHERD
	Ming-Sound Tsao, M.D.	 		 	Frances A. Shepherd, M.D.

  

 20 

 SCHEDULE A 
 Research Program 
 The Licensed Technology described under the United
States provisional patent application “Materials and Methods for Prognosing Lung Cancer”, filed on November 15, 2006 under number 10723-136/TL and as published in “Three-gene prognostic signature for early-stage non-small-cell
lung cancer”, Lau, K., et al. (2007), Journal of Clinical Oncology, relates to the identification of molecular signatures comprising a set of 3 genes and a set of 6 genes that are able to accurately segregate patients with Stage I and II
non-small cell lung cancer (“NSCLC”) into groups having good or poor prognosis. 
 These studies were performed using
snap-frozen NSCLC tumour tissues and measuring mRNA levels corresponding to these genes using quantitative real-time PCR (qPCR). These markers were identified by carrying out a large-scale, qPCR-based screen to study the prognostic power of 158
candidate biomarkers in a cohort of 147 tumour samples from NSCLC patients (collected 1996-2000). The robustness of the 3-gene and 6-gene signatures were evidenced by validation in several separate NSCLC gene expression data sets, which is
particularly significant given that these data sets: (a) were produced several years ago; (b) originate from different sites in the United States; and (c) were based on DNA microarrays. 
 The Research will focus on advancing the development of a molecular assay based on the 3- and 6-gene classifiers that would be used in clinical reference
laboratories to predict prognosis from Stage I and II NSCLC tumour samples. UHN believes that such a commercially available assay would provide to oncologists additional and valuable patient information upon which a decision would be made whether
the patient should undergo adjuvant chemotherapy. 
 Summary of Research 
 The Research for the development of the 3/6 gene signatures will be undertaken in three phases. As noted below, commencement of research on certain phases requires a positive outcome in certain prior
phases. 
 Phase 1 represents a large-scale validation study of the 3 and 6-gene signatures (but having expanded breadth for Taqman probe-based
assay development). At the end of this phase, the gene signatures will be evaluated to determine the most clinically and commercially relevant signatures. Further development will be performed based on the signature selected to form the basis for
MBI’s commercial assay. 
 Phase 2 comprises a pilot study to identify assay probe-primer sets that will perform optimally with
formalin-fixed, paraffin-embedded (“FFPE”) samples. It will also include the development of a sample processing workflow and quality control metrics for harvesting RNA from such samples. 
 Phase 3 comprises applying the 3 or 6-gene assay developed in Phases 1 and 3, as applicable, to examine prognostic ability of the markers using FFPE samples
corresponding to the same cohort of [*] patient samples from Phase 1. 
 [*] 
  

	*	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted
portions. 

 Phase 1: [*] 
 1. [*] 
 Phase 2: [*] 
 Initiation of Phase 2 is conditional upon a positive outcome of the validation of the 3/6 gene signature in Phase 1. 
 2. [*] 
 3. [*] 
 4. [*] 
 5. [*] 
  

	*	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted
portions. 

  

 2 

 Phase 3: [*] 
 Initiation of Phase 3 is conditional upon a positive outcome in Phase 1 and 2. 
 6. [*]

  

	*	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted
portions. 

  

 3 

 SCHEDULE B 
 Budget 
  

																											
	 	 	 	 	 	1st
Quarter	 	 	2nd
Quarter	 	3rd
Quarter	 	4th
Quarter	 	5th
Quarter	 	6th
Quarter	 	 	7th
Quarter	 	8th
Quarter	 	 	 	 	 Justification

	Phase 1 - Validation study for frozen NSCLC samples	 			 			 		 		 		 		 			 		 		 			 	
	[*]	 			 			 		 		 		 		 			 		 		 			 	
	Phase 1 subtotal	 	[	*] 	 			 		 		 		 		 			 		 		 	[	*] 	 	
	Phase 2 - Pilot study and assay development for FFPE samples	 			 			 		 		 		 		 			 		 		 			 	
	[*]	 			 			 		 		 		 		 			 		 		 			 	
	Phase 2 subtotal	 	[	*] 	 			 		 		 		 		 			 		 		 			 	
	Phase 3 - Large validation study of NSCLC FFPE samples	 			 			 		 		 		 		 			 		 		 			 	
	[*]	 			 			 		 		 		 		 			 		 		 			 	
	Phase 3 subtotal	 	[	*] 	 			 		 		 		 		 	[	*] 	 		 		 			 	
	Suggested Quarterly Payments	 			 	[	*] 	 		 		 		 		 			 		 		 			 	

  

	*	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted
portions. 

  

 SCHEDULE C 
 Licensed Patents 
  

	1.	UHN Existing Patents 

 Patent family entitled: “Materials and Methods for Prognosing Lung Cancer Survival” ; M.-S. Tsao et al (inventors), including: 
  

	 	(a)	US Prov. Appln. No. 60/865960 (filed Nov. 15, 2006); 

  

	 	(b)	US Appln. No. 11/940707 (filed Nov. 15, 2007); and 

  

	 	(c)	PCT Appl. No. PCT/CA2007/002039 (filed Nov. 15, 2007). 

  

	2.	UHN Research Program Patents 

 UHN Research Program Patents are to be added during the term of the Sponsored Research Agreement. 
  

	3.	Joint Research Program Patents 

 Joint Research Program Patents are to be added during the term of the Sponsored Research Agreement. 
  

	4.	Continuations, Divisionals, Renewals, Extensions 

 For greater certainty, the Licensed Patents shall include: 
  

	 	(a)	any issued patent or patent application (including any provisional patent application or any patent application filed under any international Convention or Treaty)
described or listed in this Schedule A; 

  

	 	(b)	all continuations and continuations-in-part applications to the issued patent or patent application described in Paragraph 4(a) of this Schedule A (solely to the extent
such continuations-in-part applications contain subject matter on which claims issuing obtain the benefit of a priority date of any patent or patent application described in Paragraph 4(a) of this Schedule A); 

  

	 	(c)	all divisions, patents of addition, reissues, renewals and extensions of any of the patent, patent application, continuations and continuations-in-part applications set
out in Paragraphs 4(a) and 4(b) of this Schedule A; 

  

	 	(d)	all regular utility patent applications or patent applications filed under any international Convention or Treaty on the basis of any patent application(s) described or
listed in this Schedule A; and 

  

	 	(e)	all foreign counterparts of any of the foregoing (including, without limitation, European Supplementary Protection Certificates or its equivalent).

 SCHEDULE D 
 Section 6.13 Disclosure 
  

	1)	 As disclosed effective April 14th, 2008, a 15-gene prognostic signature for non-small cell lung cancer. 

  

					
	[*]	 		  	
		 		  	
		 		  	
		 		  	

  

	*	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted
portions.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00170-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00170-of-00352.parquet"}]]